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ABSTRACT
Metabolic syndrome (MetS) can classically be defined by physiological
factors, clinical factors, and metabolic factors that are responsible for
increased risk of cardiovascular diseases (CVD) and type 2 diabetes (T2D).
The International Diabetes Federation has released the most recent definition
of MetS, defined by increased waist circumference and two of the following
factors: increased serum triglycerides or decreased HDL-cholesterol,
increased fasting blood glucose, or hypertension. MetS is also profoundly
defined by chronic low-grade inflammation. This proinflammatory state can
develop as a result adipocyte hypertrophy and hyperplasia that is responsible
for increased secretion of glycerol, free fatty acids, and secretion of
adipocytokines. States of adipose tissue dysregulation due to obesity can
directly affect systemic inflammation, and the progression to diseased states
of insulin resistance and MetS. Adipose tissue does not only contribute to the
pathophysiology through proinflammatory signaling, but can alter systemic
lipid content by releasing circulating free fatty acids (FFAs) that accumulate in
liver, induce insulin resistance in skeletal muscle, and impair pancreatic β-cell
functions, all contributing to the potential development of severe metabolic
diseases. Most importantly though, oxidative stress has been suggested to be
an early event in the pathophysiology and manifestation of chronic metabolic
disorders in humans including MetS, T2D, coronary artery disease, and
hypertension.

The excess storage of lipids in white adipose tissue (WAT), known as
obesity, results in oxidative stress and infiltration of macrophages that can
alter WAT metabolism. WAT is a metabolically active organ that is essential
for proper maintenance of systemic energy balance. WAT is a storage depot
for triglycerides, and through hormonal-signaling is responsible for the release
of energy to be utilized by tissues, such as, liver and skeletal muscle. In
addition to lipid metabolism and mobilization, WAT is responsible for glucose
homeostasis, and has major endocrine functions involving secretion of
hormones, cytokine, and transcription factors. Due to the major functions of
WAT, it is suggested that WAT plays an important role in the development of
obesity-related diseases—requiring greater knowledge and understanding of
WAT development, signaling pathways, and its role in systemic diseases.
As stated previously, oxidative stress is a unifying characteristic of
factors that contribute to MetS, and it is well established that increased lipid
content and metabolism can contribute to localized oxidative stress. Metabolic
stress within WAT can be defined as the balance between antioxidants and
oxidative stress—and publications have begun to demonstrates its effects on
adipose tissue, as it relates to metabolic diseases. Another form of oxidative
stress is achieved through the generation of reactive oxygen species (ROS) by
environmental toxicants. This form of chemical-induced oxidative stress can
also be considered important in WAT due to the highly lipophilicity and
deposition of persistent organic pollutants in adipose tissue, and the growing
concern of these chemicals to act as obesogens. Within this dissertation,

Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is addressed as a potential
responsive transcription factor to both metabolic stress and nutrient status
within a cell, and chemical-induced oxidative stress by persistent lipophilic
environmental toxicants in WAT.
Nrf2 is a nuclear transcription factor that is known to regulate
expression of antioxidant proteins in response to stimulation by oxidative
stress or inflammation. Nrf2 is still studied for its cytoprotective effects, but
has recently been shown to regulate genes involved in lipid metabolism.
Therefore, this overlap in the regulation of antioxidant response and lipid
metabolism through antioxidant response element (ARE) activation provides a
potential model for the interplay between oxidative stress and metabolic
diseases. Our lab has been able to establish the importance of Nf2 in models
of steatosis, calorie restriction in the liver, and most recently in obesity and
adipogenesis.
The purpose of the study performed in MANUSCRIPT I is to elucidate
the role of Nrf2 in calorie restriction and identify a potential mechanism of Nrf2dependent lipid regulation involved in weight loss and decreased fat storage.
Few studies exist that have shown Nrf2 activation in adipose tissue (AT), and
even fewer studies demonstrate the response of Nrf2 to nutrient status. The
data presented in this study demonstrate that 1) The ARE, Nrf2, and classical
downstream target expression is induced by calorie restriction in WAT, 2) Nrf2
induction bolsters the antioxidant capacity in vivo and in vitro, 3) Key
regulators of calorie restriction and WAT lipid metabolism are induced by an

Nrf2-dependent pathway, 4) Important enzymes involved in lipid uptake,
lipogenesis, and lipolysis are Nrf2-dependent genes, and 5) CR mimetics and
Nrf2 activators can decrease lipid content of adipocytes.
In summary, MANUSCRIPT I, demonstrates the importance of increased
antioxidant capacity to alleviate factors involved in the development of MetS,
such as: glucose intolerance, hypertriglyceridemia, and obesity. The most
significant finding is the ability of Nrf2 to respond to the nutrient status of the
organism in order to regulate signaling pathways related to energy storage
and mobilization.
Nrf2 has a novel role in its response it metabolic stressors, nutrient overload,
or nutrient deprivation, but the classical activation of Nrf2 by chemical-induced
oxidative stress can be reconsidered in understanding how environmental
contribute to development of fat mass or obesity. Many environmental
toxicants are known to stimulate the ARE/Nrf2 signaling pathway, and it has
been considered a hallmark of induction of oxidative stress. Most recently
though, environmental chemicals are more persistent in the environment and
more lipophilic, therefore being deposited in lipophilic tissues such as AT. The
ability of these compounds to activate Nrf2 may not result in an antioxidant
response, but can potentially alter the homeostasis of WAT and cause AT
dysfunction. AT dysfunction is the hallmark of many diseases, and can be
directly to related to obesity. In MANUSCRIPT II, 2,2',4,4',5pentabromodiphenyl ether (BDE-99) is studied for its ability to induce
adipogenesis and lipid development in models of pre-adipocyte differentiation.

The ability of the compound to act as an obesogen in WAT, allows for Nrf2 to
be studied in a mechanism of chemical-induced regulation of lipid metabolism.
Therefore, the purpose of MANUSCRIPT II, was to demonstrate that
environmental toxicants can alter Nrf2 expression and subsequent oxidative
stress response to alter lipid metabolism in WAT. The observations in this
study support 1) The role of BDE-99 in the development of excess lipids
during adipocyte differentiation, and 2) A potential mechanism of decreased
Nrf2-signaling during differentiation.
To summarize, MANUSCRIPT II, demonstrates the ability of an environmental
chemical to alter WAT metabolism and contribute to adiposity, through a
potential Nrf2-dependent regulation of antioxidant capacity or lipid metabolism
directly.
Lastly, MANSCURPT III, studies the ability of perinatal deltamethrin exposure
to alter WAT metabolism. The focus of this study was to demonstrate that an
environmental compound exposure during gestation and alter WAT
metabolism and result in phenotypic changes. The observations in the study
demonstrate 1) Nrf2 can be induced by chemical-exposure in WAT, 2)
Perinatal-exposure to deltamethrin has a hermetic effect on gene expression
that does not result in phenotypic changes as adults, 3) Deltamethrin could
epigenetically reprogram gene expression, and potentially be involved in the
development of susceptibility to obesity or metabolic diseases related to WAT
metabolism.

In summary, MANUSCRIPT III, represents a perinatal exposure model in
which Nrf2 is downregulated in WAT and results in a subsequent downregulation of genes involved adipogenesis, fat metabolism, and cytokine
expression.
In conclusion, this dissertation establishes a link between antioxidant
response/oxidative stress and WAT metabolism through the ARE/Nrf2
signaling pathway and continues to demonstrate that Nrf2 activation is a
hormetic effect and the timing, disease model, and length or intensity of
activation need to be considered in order to maintain homeostasis of the vital
signaling pathways regulated by Nrf2.
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PREFACE
This dissertation was prepared in manuscript format according to the
University of Rhode Island Graduate School guidelines. This dissertation
consists of three manuscripts that satisfy the requirements of the department
of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University
of Rhode Island.
MANUSCRIPT I: The role of Nrf2 activation via calorie restriction in white
adipose tissue: The cross-talk between antioxidant signaling and lipid
metabolism.
This manuscript has been prepared for submission to ‘Antioxidants & Redox
Signaling’ as an original research communication.
MANUSCRIPT II: BDE-99 increases lipid accumulation throughout
differentiation in 3T3-L1 and human pre-adipocytes in vitro.
This manuscript has been prepared for submission to ‘Toxicological Sciences’.
MANUSCRIPT III: Effects of Developmental Deltamethrin Exposure on
White Adipose Tissue Gene Expression. (J Biochem Mol Toxicol. 2013
Apr;27(4):251-2.)
This manuscript has been published in ‘Journal of Biochemical and Molecular
Toxicology’.

xi

TABLE OF CONTENTS

ABSTRACT .....................................................................................................ii
ACKNOWLEDGEMENTS .............................................................................viii
DEDICATION ...................................................................................................x
PREFACE........................................................................................................xi
TABLE OF CONTENTS ................................................................................xii
LIST OF FIGURES.........................................................................................xiii

MANUSCRIPT I ................................................................................................1
MANUSCRIPT II .............................................................................................56
MANUSCRIPT III.............................................................................................82

CONCLUSION……………………………………………………………………110

xii

LIST OF FIGURES
MANUSCRIPT I:
Figure I-1. ARE and Nrf2-target genes are induced with weight loss via calorie
restriction…......................................................................................................42
Figure I-2. Mouse ARE and Nrf2-target genes are not transcriptionally
activated in old age.,……………………………………………………………….43
Figure I-3. Decreased body weight and WAT due to calorie restriction is not
Nrf2-dependent................................................................................................44
Figure I-4. Calorie restriction induces genes involved in antioxidant response
in WAT……………………………………………………………………………….45
Figure I-5. Serum total antioxidant capacity in both male and female mice
calorically restricted……………………………………………………..………….45
Figure I-6. Nrf2 is not needed for the induction of WAT Sod1 protein and
activity by calorie restriction in female mice………………………...….………..46
Figure I-7. Ampk-P and Pparγ lipid regulation is dysregulated at the
transcriptional and protein level in Nrf2KO mice in vivo altering transcriptional
regulation of lipid uptake genes. …………………………………….…………...47
Figure I-8. Nrf2-dependent induction of rate-limiting enzyme of lipolysis,
hormone sensitive lipase ……..………………………………………….……….48
Figure I-9. Negative feedback for induction of lipogenic enzymes does not
occur in Nrf2-KO mice, but β-oxidation genes are responsive in both
cohorts…..……………………………………………………………………...……49
Figure I-10. Nrf2 and downstream targets are inducible in cultured adipocytes
resulting in increased antioxidant capacity………………………………………50
Figure I-11. Nrf2 inducing agents decrease lipid content and in cultured
adipocytes…………………………………………………………………………...51
Supplemental Figure I-1. Total tissue weights of ARE-hPAP mice fed ad
libitum or CR…………………………………………………..…………………….52
Supplemental Figure I-2. Primary human mesenteric adipocytes treated with
Ampk and Nrf2 activators demonstrated induced lipolysis ex
vivo……………………………………………………………………………….…..53
Supplemental Figure I-3. Protein expression was measured in 3T3-L1 preadipocytes following 6, 12, and 24 hr exposures………………………………..53
xiii

Supplemental Figure I-4. Decreased triglyceride content in liver due to
calorie restriction………………………………………………………………....…54
Supplemental Figure I-5. Average daily calorie intake during calorie
restriction in in vivo models……………………………………………………..…55
MANUSCRIPT II:
Figure II-1. In vitro pre-adipocyte differentiation paradigm with treatment of
environmental toxicant BDE-99. ………….………………………………………75
Figure II-2. BDE-99 induces Fas and Fabp4 during induction (Day 0-2) and
post-induction (Day 2-8) and it was demonstrated that exposure during
induction of pre-adipocytes was not needed to induce lipid accumulation...…76
Figure II-3. Increased lipid development throughout differentiation of 3T3-L1
pre-adipocytes treated with BDE-99……………………………...………………77
Figure II-4. Lower doses of BDE-99 in vitro elicit the same enhancement of
lipid development in 3T3-L1 pre-adipocytes…………………………………..…78
Figure II-5. BDE-99 decreases transcriptional expression of Nrf2 throughout
differentiation………………………………………………………………………..79
Figure II-6. Human visceral pre-adipocytes responded to BDE-99 treatment
equally, with increased lipid content in mature adipocytes……………….……80
Supplemental Figure II-1. Quantification of Fas and Fabp4. …………...…..81
Supplemental Figure II-2. Protein detection of adipogenic transcription
factors in BDE-99-treated 3T3-L1 cells………………..…………………………81
MANUSCRIPT III:
Figure III-1. ………………………………………………….……………………107
Figure III-2. ………………………………………………….……………………108
Figure III-3. ………………………………………………….……………………109

xiv

MANUSCRIPT I
Prepared for submission to the journal Antioxidants & Redox Signaling
Original Research Communication
Calorie restriction induces Nuclear Factor E2 Related Factor 2 (Nrf2) in white
adipose tissue: Antioxidant signaling and lipid metabolism.

Laura E. Armstrong1, Jialin Xu, and Angela L. Slitt1.
Department of Biomedical and Pharmaceutical Sciences, University of Rhode
Island, Kingston, RI1

Abbreviated Title: Nrf2 and Calorie Restriction
Corresponding Author:
Angela Slitt, Ph.D.
Department of Biomedical and Pharmaceutical Sciences
7 Greenhouse Rd. Kingston, RI 02881 Fax:
E-mail: aslitt@uri.edu
Word Count: (6,000): 5,916
Abstract (250 words): 365
Introduction: 902
References(75): 42
Greyscale Illustrations (8-10): 10 + 5 Supplemental Figures
Color Illustrations: 1

1

Abstract
Aim: The purpose of this study was to determine if calorie restriction (CR)
contributes to an increased antioxidant capacity and to determine the role of
Nrf2 activation in WAT; with specific focus on Nrf2-dependent and –
independent mechanisms in vivo, and AMPK and Nrf2 activation in vitro.
Nuclear factor-E2 related-factor 2 (Nrf2) is a well-established inducible
transcription factor resulting in transactivation of antioxidant response and
cytoprotective genes. CR, considered part of the primary management of
metabolic syndrome by International Diabetes Federation (IDF), is defined as
a total reduction in energy intake without nutrient deprivation. Adipose tissue
(AT) is an important endocrine organ that has recently been directly related to
the pathophysiology of metabolic syndrome through altered metabolism and
nutrient handling. Oxidative stress has most recently been shown to be an
important mediator of adipocyte dysfunction and dysfunctional adipose tissue.
Therefore, this study addresses the importance of Nrf2 and antioxidant
signaling in achieving homeostatic energy balance in white adipose tissue
(WAT) in vivo and in vitro.
Results: Data demonstrate that the antioxidant response element (ARE) and
Nrf2 are inducible in WAT by calorie restriction. CR induction of antioxidant
response is Nrf2-dependent, and Nrf2 contributes to signal transduction
pathways related to adipocyte metabolism, specifically lipid metabolism. In
WAT from ARE-hPAP mice, CR activated the ARE, and induced Nrf2 and
downstream target gene expression. Antioxidant capacity was Nrf22

dependent in WAT of female mice, and significant changes in protein
expression of p-Ampk, Pparγ, and Lpl related to lipid metabolism were
observed. Lipogenesis and β-oxidation protein expression was not altered in
Nrf2KO mice, but mRNA expression of Hsl, a lipolysis enzyme, was
transcriptionally activated in WT-CR and not in Nrf2KO mouse model. In vitro
adipocyte models illustrate that CR mimetics and Nrf2 activators induce
antioxidant gene expression, cytosolic antioxidant capacity, and decrease
triglycerides.
Innovation: This work illustrates mechanisms by which CR bolsters antioxidant
capacity in the adipose tissue. These findings establish the importance of
Nrf2-mediated antioxidant response in CR and WAT metabolism.
Conclusion: The current data support a novel role of nutrient status in the
regulation of Nrf2 and the antioxidant response in WAT, and point toward Nrf2
as a factor to combat oxidative stress and regulate lipid metabolism in WAT.
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INTRODUCTION
Adipose tissue (AT) has been underestimated in its function to regulate
metabolism and has been recently described as a vital endocrine organ. AT is
composed of adipocytes, pre-adipocytes, macrophages, and endothelial cells
that are key components in the maintenance of systemic energy balance
(Kusminski and Scherer, 2012). AT is the primary organ for lipid storage in the
form of triglycerides and release of free fatty acids (FFAs) to maintain energy
homeostasis and respond to whole-body energetic needs (Rutkowski et al.,
2015); therefore, adipocytes have a higher burden of free-fatty acids (FFA)
during normal physiological conditions compared to other cells (Kusminski and
Scherer, 2012). Due to this primary metabolic function of AT, adipocytes
tolerate a high reactive oxygen species (ROS) load that cannot be sustained
by other cells or organs without apoptosis (Kusminski and Scherer, 2012). It
has been discussed that the electron-transport chain (ETC) is the major
producer of ROS in adipocytes, with the production of superoxide anion
radicals (O2•—) and downstream secondary messenger, hydrogen peroxide
(H2O2) (Kusminski and Scherer, 2012). As reviewed by Kusminski, excess
caloric-intake is characterized by increased ROS production by the ETC and
an overload of oxidative stress associated with obesity(Kusminski and
Scherer, 2012). Increased oxidative stress associated with obesity leads to a
dysfunctional antioxidant response, as demonstrated by a down-regulation of
antioxidants such as, superoxide dismutase 2 (Sod2), glutathione peroxidase
(GPx), catalase in mouse model of metabolic syndrome (Furukawa et al.,
4

2004), and glutathione-S-transferase (GSTA4) in obese and insulin-resistant
humans (Curtis et al., 2010). WAT is also known for its ability to expand, a
function that is considered important in the protection against metabolic
abnormalities (Kusminski and Scherer, 2012). It has been demonstrated in
vitro that moderate ROS can lead to hypertrophic adipocytes due to decreased
expandability which is reversible by treatment with antioxidants; therefore,
changes in oxidative metabolism may act as signals involved in determining
lipid pool size and tissue mass in metabolic diseases (Carriere et al., 2003).
Excess ROS production is considered in the pathophysiology of diseases,
specifically metabolic syndrome, and changes in the antioxidant capacity of AT
can be assessed in order to determine beneficial mechanisms to combat these
diseases that are highly correlated to dysfunctional AT.
Calorie restriction (CR) is considered part of the primary management of
metabolic syndrome by International Diabetes Federation (IDF) and is defined
as a total reduction in energy intake without nutrient deprivation. Dietary
intervention in humans is the most effective therapy to combat metabolic
syndrome (Lopez-Legarrea et al., 2013). The underlying mechanism of
metabolic syndrome and an effective pharmacological target have not been
identified in order to treat the disease as a whole. The IDF has defined
metabolic syndrome as an individual having central obesity and two of the four
precursors to disease: dyslipidemia (increased triglycerides or lowered HDLcholesterol), insulin-resistance (increase fasting blood glucose), or
hypertension (increased blood pressure). Oxidative stress and dysfunctional
5

AT can be linked to each of these states in human studies (Bremer et al.,
2011; Bremer and Jialal, 2013; Furukawa, Fujita, Shimabukuro, Iwaki,
Yamada, Nakajima, Nakayama, Makishima, Matsuda and Shimomura, 2004;
Roberts and Sindhu, 2009; Vincent and Taylor, 2006). The RESMENA study,
in which a novel dietary strategy was compared to the American Heart
Association (AHA) guidelines for dietary components, revealed that dietary
total antioxidant capacity (TAC) was the predominant factor in decreased body
weight, BMI, and fat mass (Lopez-Legarrea, de la Iglesia, Abete, Bondia-Pons,
Navas-Carretero, Forga, Martinez and Zulet, 2013). Dietary TAC compared to
other dietary aspects is most relevant to decrease in markers of obesity and
metabolic syndrome (Abete et al., 2010; Lopez-Legarrea, de la Iglesia, Abete,
Bondia-Pons, Navas-Carretero, Forga, Martinez and Zulet, 2013; Puchau et
al., 2009). Therefore, understanding the mechanism by which CR maintains
energy homeostasis in AT without production of excess ROS may be essential
in determining an effective pharmacological treatment of metabolic syndrome.
CR has been shown to transcriptionally induce a battery of antioxidant
genes in liver accompanied by Nrf2 expression, and this antioxidant response
was attenuated in Nrf2KO mice (Pearson et al., 2008). Nrf2 was demonstrated
to be inducible in WAT through Keap1-KD and pharmacological activators (Xu
et al., 2012). The transcription factor has been classically defined to regulate
the basal and inducible expression of genes, and is negatively regulated by
Kelch-like ECH-associated protein 1 (Keap1) due to sequestration in the
cytoplasm (Klaassen and Reisman, 2010; Niture et al., 2010). During periods
6

of cellular stress, by endogenous or exogenous increases in ROS and
electrophiles, Nrf2 translocates to the nucleus, where it heterodimerizes with
small Maf protein and activates the antioxidant response element (ARE)
(Nguyen et al., 2009; Niture, Kaspar, Shen and Jaiswal, 2010). Activation of
the ARE has been characterized to regulate genes involved in antioxidant
response, and most notably Nrf2 is known to induce Phase I- and II- drug
metabolizing enzymes and transporters for the elimination of potentially
harmful xenobiotics (Klaassen and Reisman, 2010). More recently, in both
liver and WAT Nrf2 expression has been shown to be directly related to lipid
content and body weight changes. Our laboratory was able to show that
constitutive activation of Nrf2 by Keap1-KD in vivo enhanced the reduction of
liver triglycerides and non-esterified fatty acids (NEFAs) via CR by
upregulation of β-oxidation genes (Kulkarni et al., 2013), and constitutive Nrf2
activation also repressed HFD-induced obesity and lipid accumulation in WAT
in vivo (Xu, Kulkarni, Donepudi, More and Slitt, 2012). A previous study
showed that the prototypical Nrf2 activating compound, CDDO- Imidazolide,
increased weight loss in HFD-mice (Shin et al., 2009). There was also a
positive relationship between hyperlipidemia and Nrf2 activation (Xu, Kulkarni,
Donepudi, More and Slitt, 2012) suggesting that this well-described
transcriptional regulator of the antioxidant response may have a potential role
in the regulation of oxidative stress and lipid homeostasis in WAT.
The purpose of this study was to identify whether 1) CR can induce the ARE
and Nrf2-dependent gene expression in WAT, 2) WAT weight loss and lipid
7

homeostasis is Nrf2-dependent, and whether CR mimetics and Nrf2 activators
can directly alter the antioxidant capacity of adipocytes to regulate WAT mass.
Data presented herein describes CR induction of the Nrf2 pathway and
antioxidant response in WAT, as well as the role of Nrf2 in decreased fat mass
upon CR.

8

RESULTS
CR induces the antioxidant response transcriptionally in WAT of mature
ARE-hPAP mice, and Nrf2 induction is age-dependent.

The 40% CR was

effective, as illustrated by a 36% loss of body weight (BW) (Fig. 1A), as well as
WAT weight and 53.5 mg/dL decrease in blood glucose levels after 5 weeks of
CR compared to ad libitum (AL) (Supplemental figure 1; Fig. 1B). Induction of
the ARE, measured by human alkaline phosphatase (hPAP) expression, was
only achieved in WAT (2-fold increase), whereas Nrf2 and downstream
targets, Nqo1 and Gclc, were all induced greater than 2-fold in both WAT and
skeletal muscle (SKM) (Fig. 1C). For this CR paradigm, ARE-hPAP and Nrf2
targets were not significantly altered (Fig 1C), although decreased liver weight
was observed (Supplemental Figure 1). Data from a second cohort of AREhPAP mice separated by age, Mature (average age of 16-wks ± 25.5) versus
Old (average age of 97-wks ± 16), illustrated that Nrf2 and Nrf2-target genes
were inducible in the cohort of mature age, without induction of the ARE (Fig.
2A), but not inducible by CR in old age even with induction of the ARE (Fig.
2B). The difference in expression and induction of genes may be due to large
standard deviation in age of second cohort of mature ARE-hPAP mice.
CR reduction in body weight and WAT is not Nrf2-dependent in both
male and female mice. To determine if Nrf2 is an integral signaling pathway
in CR and if the reduction of WAT weight is Nrf2-dependent, male and female
Nrf2KO mice were placed on a 40% and 25% calorie-restricted diet,
respectively. BW and WAT weight were measured. In both male and female
9

Nrf2KO mice on CR, BW and WAT weights were not significantly different
from wild-type (WT) mice CR (Fig . 3 A and 3B). Ad libitum Nrf2KO mice have
a decreased initial body weight and WAT weight compared to WT (Fig. 3B);
these data are consistent with previous publications that demonstrate the
importance of Nrf2 for adipocyte differentiation (Hou et al., 2012; Pi et al.,
2010). CR decreased body and WAT weight similarly in male and female WT
and Nrf2KO mice CR increased Nrf2 and Nqo1 mRNA expression in WT, but
not Nrf2KO WAT (Fig. 3B and 3C), which Nrf2 and Nqo1 gene expression in
WT WAT was similar to that observed in the ARE-hPAP mice (Fig. 1C); with
Nrf2 and Nqo1 expression being induced by at least 2-fold respectively (Fig.
3C).

CR induces the antioxidant response in WAT and serum antioxidant
capacity in vivo. CR doubled Gclc mRNA in WAT of both male and female
mice, but not in Nrf2KO mice (Fig 4A), whereas catalase mRNA expression
was increased similarly (2-3-fold) in both WT-CR and Nrf2KO-CR (Fig. 4B).
Subsequently, serum antioxidant capacity (AOC) was measured by ORAC
assay in order to assess whether CR bolstered the antioxidant capacity in
WAT. Male and female serum AOC was determined after 5 and 6 weeks of
CR, respectively. CR increased AOC in male and female WAT (Fig 5A and
B), but this induction was only significantly Nrf2-depdendent in females, with
AOC in Nrf2KO being similar to WT-AL fed females (Fig. 5B).

10

Sod1 increased protein and activity by calorie restriction in female mice
is Nrf2-indepednent, and proposed to be a potential WAT factor in
systemic glucose homeostasis and hepatic gluconeogenesis. Induced
oxidative stress in obese and diabetic mice has been shown to decrease Sod1
in WAT (Furukawa, Fujita, Shimabukuro, Iwaki, Yamada, Nakajima,
Nakayama, Makishima, Matsuda and Shimomura, 2004), and models of Sod1
activation have decreased glucose intolerance and lipid peroxidation caused
by HFD. To determine whether Sod1 is regulated via Nrf2 upon CR and
contributes to changes in systemic glucose metabolism: Sod1 mRNA, protein,
and enzyme activity was measured. Glucose tolerance (GTT) and pyruvate
tolerance tests (PTT) were carried out in WT and Nrf2KO mice. Nrf2 was
observed to contribute to an increase in Sod1 mRNA upon CR (Fig. 6A), but
post-transcriptional changes may be responsible for significantly induced
protein expression in both WT and Nrf2KO mice (Fig. 6B). Lastly, CR induced
the enzymatic activity of Sod1 in WT-CR and Nrf2KO-CR mice, supporting
protein expression observations (Fig. 6C). Blood glucose levels were
measured throughout the study and there was no difference in response to CR
in the absence of Nrf2, with no significant difference between WT-CR and
Nrf2KO-CR blood glucose levels (Figure 6D). Subsequently, CR increased
glucose tolerance in WT mice, but Nrf2KO mice basally had significant
increase glucose tolerance compared to WT-AL (Fig. 6E). Hepatic
gluconeogenesis was induced in both WT and Nrf2KO mice, as demonstrated
by an increased pyruvate tolerance, and to the same extent (Fig. 6F).
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Therefore, Sod1 was shown to be induced without Nrf2 activation, and
beneficial effects on glucose metabolism were not dependent on Nrf2,
suggesting a role of Sod1 in preventing oxidative stress that
contributes to glucose intolerance and decreased gluconeogenesis in models
of obesity.

p-Ampk and Pparγ lipid regulation is dysregulated at the transcriptional
and protein level in Nrf2KO mice in vivo altering transcriptional
regulation of lipid uptake and lipolysis genes. The major transcription
factors of CR, p-Ampk, and adipogenesis and lipid metabolism, Pparγ, were
measured to assess whether CR induced changes in AMP:ATP ratio and
altered lipid metabolism are Nrf2-dependent. Ampk activation by
phosphorylation was shown to be Nrf2-dependent in both male and female
mice, but only female WT mice had a significant induction in protein
expression upon calorie restriction (Fig. 7B). Both male and female mice
demonstrated a significant increase in Pparγ with CR, but only female mice
showed an Nrf2-dependent response (Fig. 7B). Lpl and Cd36, involved in lipid
uptake from the serum, did show consistent protein expression between male
and female mice and Nrf2 regulation, except that both males and females did
not show a significant increase in Lpl upon calorie restriction (Fig. 7B). Protein
expression of these key factors in lipid mobilization did not reflect their mRNA
expression or transcriptional activation by Nrf2 (Fig. 7A). Therefore, there may
be alterations in post-transcriptional modifications or protein turnover in calorie
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restriction and Nrf2KO model. Lastly, Hsl transcriptional activation by CR was
demonstrated to be Nrf2-dependent (Fig 8A). This reflects another
downstream target of Pparγ.

Induction of β-oxidation genes is not Nrf2-dependent, while negative
feed-back for induction of lipogenic enzymes is dysregulated in Nrf2KO
mice. Key enzymes involved in both lipogenesis and fatty acid β-oxidation
were measured to further assess the physiological response of WAT to CR
and potential role of Nrf2. β-oxidation was not altered by Nrf2KO, as
demonstrated by 2-fold or greater induction of transcriptional regulators, Pgc1α and Pparα, and enzymes involved in the initial steps of β-oxdiation, Acadm
and Eehad (Fig 9C). Genes involved in lipogenesis were not consistently
transcriptionally activated by Nrf2. Srebp1c and Fas were induced in both
WT- and Nrf2KO-CR mice by 7.3- and 6.5-fold and 9- and 8-fold, respectively
(Fig. 9A). Other key enzymes in lipogenesis in WAT, Acc-1 and Scd-1, were
shown to be induced upon CR by 16- and 6.4-fold, but Nrf2 acts as a
coactivator for their transcriptional activation as demonstrated by a
significantly decreased induction in Nrf2KO-CR mice, 10.5- and 3.7-fold,
respectively (Fig. 9A). All mRNA expression was analyzed in female mouse
models of CR, but Nrf2-coactivation of Acc upon CR was reflected at the
protein level in both male and female mice (Fig. 9B).
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Calorie restriction mimetic, AICAR, and Nrf2 activators, oltipraz and
sulforaphane induce the antioxidant response in vitro and decrease lipid
load of mature adipocytes. Two well accepted models of differentiated
mature adipocytes, 3T3-L1 pre-adipocytes and MEFs were used to study the
effect of calorie restriction and Nrf2 activation in vitro. AICAR and oltipraz
induced Nrf2 and transcriptional expression of downstream genes Nqo1 and
Gclc in mature 3T3-L1 pre-adipocytes, and sulforaphane induced only Nqo1
significantly at the mRNA level (Fig10A). In mature 3T3-L1 pre-adipocyte
model mRNA expression correlated with induction of cellular antioxidant
capacity and Nqo1 protein expression (Fig. 10B and 10C). p-Ampk was
induced by AICAR and oltipraz at 6 and 12 h post-treatment, and Nqo1
remained induced (Fig. 10C). Total AMPK was increased at 12 h and 24 h
post-treatment (Supplemental Fig 3). Sulforaphane induced both p-Ampk and
Nqo1 at 6 h, but protein expression did not remain stable (Fig. 10C). RLU
quantification of all blots was determined (n=1) and represented in
Supplemental Figure 3, in addition to total Ampk and β-Actin blots as controls.
All 3 treatments induced the Nrf2-dependent antioxidant response cascade;
therefore, in order to study if Nrf2 activation contributes to decrease in lipid
content of adipocytes the lipid profile of mature MEFs and 3T3-L1 preadipocytes was examined. Both models showed significant decrease in
triglycerides with Ampk and Nrf2 activation. Triglyceride concentration was
decreased significantly in MEFs and 3T3-L1 model by Aicar, 28% and 39%,
oltipraz 19% and 42.5%, and sulforaphane 38%, respectively (Fig. 11A). In
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preliminary MEF experiments Sirt1720, a calorie restriction mimetic through
activation of Sirt1, showed no significant decrease in triglycerides (Fig. 11A).
Total lipid content, measured by oil red o staining, was reduced with 48 h
treatment of AICAR, oltipraz, and sulforaphane in 3T3-L1 pre-adipocytes (Fig
11B).
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DISCUSSION
Nrf2 is a transcription factor historically studied for its cytoprotective effects,
and has recently been demonstrated to be a nutrient responsive factor and a
key regulatior of lipid metabolism. In the present study Nrf2 was demonstrated
to be transcriptionally induced in WAT by CR in vivo resulting in upregulation
of antioxidant signaling. Other studies have only demonstrated an increase in
Nrf2 upon CR by measurement of Nrf2, Nqo1, and other downstream targets’
activation in liver (Fu and Klaassen, 2014; Pearson, Lewis, Price, Chang,
Perez, Cascajo, Tamashiro, Poosala, Csiszar, Ungvari, Kensler, Yamamoto,
Egan, Longo, Ingram, Navas and de Cabo, 2008). CR was demonstrated to
induce Nrf2 activation in WAT by subsequent activation of the ARE, Nqo1 and
Gclc; therefore, this study supports our laboratory’s findings that the
ubiquitously expressed transcription factor responds to nutrient stimulus in
multiple metabolically active tissues (Kulkarni, Armstrong and Slitt, 2013;
Kulkarni et al., 2014; Xu, Kulkarni, Donepudi, More and Slitt, 2012). In
addition, CR-activation of Nrf2 was demonstrated to be physiologically
important in inducing total serum antioxidant capacity. TAC in humans has
been negatively correlated to increased central fat and obesity in both males
and females, with reduced TAC by 5-7% and 6-10%, respectively, with
females having a greater reduction in TAC (Chrysohoou et al., 2007).
Therefore, more recent studies have focused on the effect of increased TAC
through dietary interventions (Lopez-Legarrea, de la Iglesia, Abete, BondiaPons, Navas-Carretero, Forga, Martinez and Zulet, 2013; Puchau, Zulet, de
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Echavarri, Hermsdorff and Martinez, 2009). Specifically, dietary TAC intake
was a major factor in body weight, waist circumference, and fat mass
decreases in the REMENA-S study (Lopez-Legarrea, de la Iglesia, Abete,
Bondia-Pons, Navas-Carretero, Forga, Martinez and Zulet, 2013). The
induction of Nrf2 in WAT by calorie restriction contributed to an overall
systemic induction of TAC without correlation to increased weight loss in mice,
which differs from human data. Further studies need to address localized TAC
levels and the direct role of WAT regulation in systemic TAC.
It is previously reported that oxidative stress is directly related to obesity,
glucose intolerance, and insulin resistance—specifically superoxide anion
radicals (O2•—) are a common feature across models of insulin resistance
(Hoehn et al., 2009) and decrease in WAT Sod1 is associated with murine
models of severe obesity, hyperlipidemia, and insulin resistance(Furukawa,
Fujita, Shimabukuro, Iwaki, Yamada, Nakajima, Nakayama, Makishima,
Matsuda and Shimomura, 2004). Also, WAT oxidative stress has been
demonstrated to effect insulin resistance with alterations in ROS linked to
changes in insulin sensitivity in 3T3-L1 preadiocytes (Kusminski and Scherer,
2012). In our study we were able to demonstrate that Nrf2 was not necessary
to enhance glucose tolerance and hepatic gluconeogenesis, and Sod1
induction, a major enzyme responsible in reducing cellular oxidative stress,
was not Nrf2-dependent; therefore, it can be suggested that Sod1 may be a
key enzyme in maintaining glucose homeostasis. This notion is supported by
previously published data that demonstrate: the deleterious effects of Sod1 on
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glucose homeostasis and lipid metabolism (Wang et al., 2012), the beneficial
effects of Sod1 overexpression to decrease glucose intolerance and lipid
peroxidation caused by a high-fat diet (Liu et al., 2013), and the induction of
Sod1 in ob/ob mice by rosiglitazone to ameliorate insulin insensitivity
(Takazawa et al., 2009). The post-transcriptional modification or alteration in
protein degradation is noted in our study due to discrepancies between Nrf2
transcriptional regulation of Sod1 and Sod1 protein and activity. This
observation should be further investigated as another study has demonstrated
the same regulation of Sod1 in WAT by exercise training (Sakurai et al., 2009).
CR and P-Ampk have been previously studied in the context of Ampk as an
energy sensor of intracellular adenosine levels and is activated by increased in
AMP:ATP or ADP:ATP levels that can be due to cellular stress, low nutrients,
and prolonged exercise (Mihaylova and Shaw, 2011). Ampk is responsible for
regulating catabolic and anabolic pathways by phosphorylation of proteins and
has been reviewed to regulate metabolic transcription factors or enzymes in
fatty acid synthesis, inactivation of Srebp1 and ACC in liver, or lipolysis, HSL
and ATGL in adipose, to restore ATP levels (Mihaylova and Shaw, 2011). An
activator of AMPK is AICAR, which mimics AMP binding to the Ampkγ
subunits (Mihaylova and Shaw, 2011). In the present study we were able to
demonstrate that calorie restriction induced phosphorylation of Ampk in vivo,
and p-Ampk was inducible by AICAR (6 hr exposure), oltipraz (12 hr
exposure), and sulforaphane (24 hr) in vitro. In vitro modeling in preadipocytes demonstrated a potential cross-talk between Ampk activation and
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Nrf2 activation, in which AICAR induced p-Ampk and Nqo1 at 6 and 12 hrs,
and oltipraz subsequently induced Nqo1 prior to its induction of p-Ampk.
Recent publications support a cross-talk between Ampk and Nrf2 in
proinflammatory macrophages treated with an Ampk activator, in which the
data demonstrate that Nrf2 activation is Ampk-dependent and the antiinflammatory effect of the Ampk activator is Nrf2-dependent (Mo et al., 2014).
The data presented in vivo demonstrated that Ampk phosphorylation was not
induced by calorie restriction in Nrf2KO mice in both sexes. Therefore, the
response to metabolic stressors in metabolically active tissues, specifically
WAT in the present study, may be dependent on the cross-talk between Ampk
and Nrf2. Additional studies should be developed to determine which nutrient
responsive factor is upstream in the signaling cascade or if they are
coordinately regulated in states of metabolic stress.
The study of key regulatory pathways in adipocyte metabolism of both male
and female mice contributes to the understanding of the role of Nrf2 in lipid
homeostasis and the relationship between oxidative stress and lipid
metabolism. In WAT transcriptional activation of Nrf2 is responsible for CRinduction of Pparγ, a master regulator of adipogenesis and lipid metabolism.
Pparγ maintains metabolic homeostasis in adipose tissue, in which it is
predominately expressed, that systemically protects against lipid overload in
alternate tissues and maintains a balanced secretion of adipocytokines,
predominantly involved in systemic insulin sensitivity (Janani and Ranjitha
Kumari, 2015). Pparγ is known for its transcriptional regulation of Lpl and
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Cd36, genes directly involved in the uptake of lipids from serum, and the
regulation of genes in lipogenesis or the stimulation of storage of fatty acids in
mature adipocytes and WAT expandability(Janani and Ranjitha Kumari, 2015).
Our findings provide in vivo data through CR-induced Nrf2 activation that
supports previous findings that Nrf2 activates the Pparγ promoter activity in
vitro (Pi, Leung, Xue, Wang, Hou, Liu, Yehuda-Shnaidman, Lee, Lau, Kurtz
and Chan, 2010). Nrf2 was demonstrated to be involved in the transcriptional
activation of both Lpl and Cd36, either independently or as a coactivator,
respectively.
In addition to Nrf2 regulation of Pparγ and Lpl, Hsl gene expression was
dependent on CR-induced Nrf2 activation, and initial in vitro data support the
role of Nrf2 activation on activation of lipolysis upon CR (data not presented,
Supplemental Figure 2). Nrf2 activation was also shown to contribute to the
activation of key enzymes involved in lipid storage, Acc-1 and Scd-1, which
demonstrate the role of Nrf2 activation in adipose tissue expandability. Lastly,
CR-induction of β-oxidation in adipocytes was not Nrf2-dependent, but it is
well-established that Pgc1-α is a master regulator of cellular energy
metabolism and under normal conditions has a low expression level in WAT,
but with increased mitochondrial biogenesis and oxidative metabolism Pgc1-α
activation may be the predominant activator of downstream β-oxidation gene
expression (Liang and Ward, 2006). Therefore, our models of CR and
utilization of the Nrf2KO mouse model demonstrated not only the role of Nrf2
in CR-induced changes in lipid uptake and lipolysis, but other potential key
20

regulators in WAT metabolism that are responsive to CR specifically related to
oxidative metabolism.
The study not only demonstrated CR-induced Nrf2 activation in vivo, but the
ability of the CR mimetic AICAR and Nrf2 activators, oltipraz and
sulforaphane, to increase cellular antioxidant capacity and decrease lipid
content in two in vitro models of mature adipocytes. The in vitro findings
further support a direct interplay between oxidative stress or antioxidants and
lipid metabolism. As stated previously all compounds were able to activate
both p-Ampk and Nqo1, with varying degrees of induction, and produce
equivalent physiological effects as seen in our in vivo modeling of CR. Our
data specifically support previously published data that have demonstrated
oltipraz, a small molecule activator of Nrf2, and sulforaphane, an organic
phytochemical inhibitor of Nrf2 degradation, attenuates fat gain in high-fat diet
fed mice (Yu et al., 2011) and inhibit lipid accumulation in MEFs (Xu, Kulkarni,
Donepudi, More and Slitt, 2012), respectively. These data further represent
the concept that Nrf2 is protective in various cell types (liver, lung, GI tract,
kidney, skin, neurons, and macrophages), and the ubiquitously expressed
protein coordinately regulates not only ARE-driven gene expression, but cell
type-specific protective genes, which results in a bolstered local and systemic
defense system (Lee et al., 2005).
Recent publications support our overall finding that Nrf2 is inducible in WAT
and plays a pivotal role in adipocyte metabolism to alter systemic
pathophysiology of disease models. Specifically, global and adipose-specific
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Nrf2 deficiency correlated to a reduction in WAT mass and suppression of prolipogenic and inflammatory genes and proteins, but resulted in worsened
characteristics of metabolic syndrome (Xue et al., 2013). At the other
extreme, constitutive Nrf2 activation in leptin-deficient mice also impaired lipid
accumulation in adipocytes and resulted in worsened insulin resistance and
hepatic steatosis by, reduction in insulin-signaling molecules in adipose and
increase gene expression of pro-lipogenic factors in liver (Xu, Kulkarni,
Donepudi, More and Slitt, 2012). Our model demonstrated an overall
beneficial effect of Nrf2 activation by calorie restriction to alleviate metabolic
stress and contribute to decreased lipid storage in WAT and liver
(Supplemental Figure 4). The notion that the benefits of Nrf2 activation are
hormetic (Maher and Yamamoto, 2010; Taguchi et al., 2010) is equally
supported by our findings and previous publications; therefore, making it a
difficult systemic drug target in diseased states. Overall, the study was able to
show that tissue-specific regulation of Nrf2 in adipose tissue can be described
as a mechanism to combat metabolic diseases associated with oxidative
stress and excess lipids in the presence of a healthy leptin-axis, and identified
the potential therapeutic benefit of Ampk and Nrf2 cross-talk.

22

INNOVATION
The data presented show a novel role of Nrf2 in calorie restriction related to
WAT metabolism, and further contribute to potential mechanisms related to
recently published data supporting the beneficial effects of antioxidant-rich
dietary components and the overall beneficial effects of induced antioxidant
capacity in calorie restriction. These novel findings can provide insight into
future pharmacological targets for the underlying oxidative stress in multiple
precursors of metabolic syndrome, and subsequent metabolic diseases. The
ability to induce the ARE and subsequent Nrf2 gene expression in WAT of
ARE-hPAP mouse model has never been described.
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MATERIALS AND METHODS
Animals and treatments.

Three animal models were used for the following

animal studies: ARE-hPAP transgenic reported mice from Dr. Jeff Johnson’s
laboratory (Johnson et al., 2008), C57Bl/6 (wild-type, WT) mice purchased
from Charles River Laboratories (Frederick, MD), and Nrf2KO mice shared
from Dr. Curtis D. Klaassen’s laboratory (University of Kansas Medical
School). All animal studies and procedures were carried out in accordance
with and approved by the Institutional Animal Care and Use Committee at the
University of Rhode Island. Adult 16-week old (n=9) ARE-hPAP transgenic
reporter mice, and adult 14-week old male and female C57Bl/6 (n=10, n=16)
and Nrf2KO (n=15, n=22) mice were monitored for food intake for 2 weeks,
and average daily calorie intake was determined based on consumption of
normal chow—Harlan Teklad LM-485 Mouse/Rat Sterilizable Diet (Harlan
Laboratories, Indianapolis, IN) for 1 week, followed by purified and nutrientrich chow—AIN-93G Growth Purified Diet (TestDiet, St. Louis, MO) during
week 2. At 18 weeks and 16 weeks, respectively, ARE-hPAP and C57Bl/6 and
Nrf2KO mice were separated equally into two groups: ad libitum and calorie
restricted (40% of daily average calorie intake for males, and 25% for
females). Calorie restricted mice were fed AIN-93G Growth Purified Diet
based upon food weight equivalent to initial calculated daily calorie intake. All
cohorts received 6.62-7.72 kCal/day during calorie restriction (Supplemental
Figure 5). All cohorts were maintained on experimental diets (ad libitum or
calorie restricted) for 5 to 6 weeks prior to sacrifice. Body weight (BW) was
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measured weekly and blood glucose (BG) was measured every 2 weeks via
tail vein bleed with Bayer® Contour glucometer and corresponding blood
glucose test strips. Prior to necropsy BW and BG were measured, and at time
of necropsy white adipose tissue (WAT) and liver weights were measured. All
tissues collected (liver, WAT, and skeletal muscle) were snap frozen in liquid
nitrogen and stored at -80°C.
Glucose and Pyruvate Tolerance Tests (GTT and PTT). After a 16-hr fast
both male and female cohorts received an i.p. injection of 2 g/kg of glucose
(Sigma-Aldrich, St Louis, MD) for the GTT. Pyruvate was administered as an
i.p, injection of 2 g/kg of sodium pyruvate (Sigma) following an 18-hr fast for
both male and female cohorts. Fasting blood glucose concentrations were
taken prior to the injections and 15, 30, 60, and 120 minutes post-injection. All
glucose concentrations were measured via tail vein bleed using a Bayer®
glucometer following IACUC protocol.
Media, Reagents, and Chemicals. Dulbecco's Modified Eagle Medium
(DMEM) high glucose (4.5 g/L) with L-glutamine (Lonza), DMEM/F-12 (Gibco),
Fetal Bovine Serum (FBS, Gibco), and penicillin-streptomycin (pen-strep) was
purchased from ThermoFisher Scientific (Waltham, MA). Oltipraz was
purchased from LKT laboratories (#04578, St Paul, MN) and Sirt1720 is a
Selleck Chemicals, LLC compound (#51129, Pittsburg, PA). All other
chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, MO):
Dimethyl Sulfoxide (DMSO), 5-Aminoimidazole-4-carboxamide 1-β-D-
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ribofuranoside (AICAR), L-Sulforaphane, 3-isobutyl-1-methylxanthine (IBMX),
Dexamethasone (DEX), human insulin solution, and Oil Red O, specifically.

Primary mouse embryonic fibroblast (MEF) isolation, differentiation, and
treatment.

Primary MEF isolation from ARE-hPAP mice and differentiation

to mature adipocytes was performed as described (Xu et al., 2015). Following
differentiation, day 9 mature MEFs were treated with DMEM containing 10%
FBS and 1% pen-strep supplemented with DMSO (0.1%), AICAR (500 μM),
Oltipraz (100 μM), or Sirt1720 (10 μM) for 4 days with media changed 2 days
post-treatment. MEFs were analyzed for lipid development, lipid content, and
mRNA expression.
3T3-L1 pre-adipocyte cell culture, differentiation, and treatment.

Mouse

3T3-L1 pre-adipocytes (ATCC® CL-173™) were obtained from American
Type Culture Collection (ATCC, Manassas, VA) and were cultured following
ATCC protocol utilizing. 3T3-L1 pre-adipocytes were induced and
differentiated according to previously described protocol (Shin, Wakabayashi,
Yates, Wakabayashi, Dolan, Aja, Liby, Sporn, Yamamoto and Kensler, 2009;
Xu, Kulkarni, Donepudi, More and Slitt, 2012). Briefly, 48 h post-confluent
cells were induced by induction media (Maintenance media (DMEM, 10%
FBS, and 1 % p/s) supplemented with 0.5 mM IBMX, 0.2 mM DEX, and 10
μg/mL insulin) for 48 h and then differentiated only in the presence of insulin
(10 ug/mL) for 6 days. At day 8, cells are considered mature with the
formation of lipid droplets and maintained in DMEM supplemented with 10 %
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FBS, and 1% pen-strep (maintenance media). Mature 3T3-L1 pre-adipocytes
were treated at Day 8 with maintenance media supplemented with DMSO
(0.1%), AICAR (500 μM), Oltipraz (100 μM), or Sulforaphane (10 μM) for 24
and 48 h. 3T3-L1 pre-adipocytes were analyzed for lipid development, lipid
content, mRNA and protein expression, and antioxidant capacity.
Cellular Lipid Development—Oil Red O Staining.

Mature MEF and 3T3-

L1 pre-adipocytes were stained for lipid development in 12-well plates (n=3
per treatment). Following treatment the media was removed and cells were
gently washed with PBS and fixed with 10% acetate-buffered formalin
(ThermoFisher Scientific, Waltham, MA) for 1 h. Oil Red O stock solution
(0.6%) was prepared in 100% isopropanol. Oil Red O working solution was
made directly prior to staining by combining Oil Red O stock solution and DI
water 3:2 v/v, allowing the solution to sit for 10 mins, and then filtering the
solution. Following fixation, the cells were washed and stained with Oil Red O
working solution for 15 mins. The cells were then rinsed with water until the
water rinsed clear. Cells were stored and imaged in DI water. Oil Red O
images were taken at 20x magnification (EVOS, Life Technologies, Carlsbad,
CA), and Oil Red O staining was quantified by ImageJ software (National
Institute of Health) following the previous published protocol (Mehlem et al.,
2013).
Lipid Isolation and Quantification—Triglycerides.

Triglyceride

concentrations from MEF and 3T3-L1 cells were measured from 1 mL PBS
lysates (6-well plates; n=3/group) collected after 48 h treatment. 200 μl of
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lysate was transferred to 15 mL screw-capped tube containing 3.75 mL
chloroform-methanol (2:1, v/v) solution. Water (0.5 mL) was added and
centrifuged at 3000 rpm for 5 min at room temperature. The chloroformmethanol layer containing lipids was transferred to glass tube and evaporated
to dryness in a fume hood overnight. The completely dried lipid residue was
resuspended in 200 ul of 1% Triton X-100 in 100% ethanol. Extracted lipids
and serum were measured for triglyceride content using the microtiter protocol
for Triglycerides GPO-Reagent Kit (Pointe Scientific, Canton, MI). Briefly,
standard and samples (3 μl) were run in triplicate on a 96-well plate by adding
250 μl of reconstituted triglyceride reagent, and absorbance was read at 540
nm on Spectramax M2 (Molecular Devices, Sunnyvale, CA). Cellular
triglyceride content was expressed as a ratio of triglyceride concentration
(mg/dL) to total protein concentration (mg/dL) of lysates determined by DCTM
Protein Assay (Bio-Rad Laboratories, Hercules, CA).
Messenger RNA quantification.

Total RNA was isolated from tissues or

cells using TRIzol reagent (Invitrogen, Carlsbad, CA) following manufacturer
protocol, and quantified following cDNA synthesis (Transcriptor First Strand
cDNA Synthesis Kit) via LightCycler 480® SYBR Green I Master chemistry
(Roche Applied Sciences, Indianapolis, IN). All gene primers (Supplemental
table 1) were utilized at a final concentration of 0.5 μM with a final
concentration of cDNA template of 50-60 ng.
Oxygen Radical Antioxidant Capacity Assay (ORAC).

Whole blood was

collected at time of necropsy and incubated on ice for 2 h prior to
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centrifugation at 8,000 xg at 4°C for . Serum was collected and stored at 80°C. 3T3-L1 cytosolic cellular fractions were collected from NE-PER Nuclear
and Cytoplasmic Extraction Kit (ThermoFisher Scientific, Waltham, MA)
following the manufacturer protocol. Mouse serum and 3T3-L1 media and
cytosolic cellular fractions were diluted 1:500 and 1:100, respectively. The
ORAC assay protocol by BioTek® (citation) was optimized for the
Spectramax M2 (Molecular Devices, Sunnyvale, CA) using sensitivity=6 and
bottom-reader for a 96-well clear-bottom plate. Trolox standards and samples
were pipetted in replicate (25 μl) with 150 μl of 2 μM fluorescein and
fluorescence (485nm, 528nm) was measured over 1 h every minute
immediately following addition of the radical generator 2,2'-Azobis(2amidinopropane) dihydrochloride (AAPH). The total AUC was calculated on
GraphPad Prism Software (La Jolla, CA).
Western blotting.

Western blots were used for identification and

quantification of WAT and 3T3-L1 pre-adipocyte proteins from total cell lysates
in RIPA buffer. Protein was electrophoretically separated by SDSpolyacrylamide gel electrophoresis. The gel was transblotted on PVDF
membrane (Bio-Rad Laboratories, Hercules, CA) at 100 V for 1 h. The
membrane was blocked for 1 h (room temperature) with 5% non-fat dry milk in
tris-buffered saline with 0.1% Tween 20 (TBS-T). The membrane was then
incubated with primary antibody in 5 % BSA in TBS-T at 4°C overnight. After
washing, the membrane was incubated with species-specific HRP-conjugated
secondary antibody for 1 h at room temperature. Specific antibody information
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and conditions are provided in Supplemental Table 2. The blots were
incubated in Clarity™ Western ECL Blotting Substrate (Bio-Rad Laboratories,
Hercules, CA) and were visualized using autoradiography film. Protein bands
were quantified using ImageJ (National Institute of Health) and all bands were
normalized to corresponding β-Actin protein quantification.
Statistical Significance. Student’s T-test was performed to determined
statistical significance between ARE-hPAP mice fed ad libitum or CR, unless
otherwise stated (p<0.05*, p<0.01**, p<0.001***, p<0.0001****). Statistical
significance was determined between WT-AL, WT-CR, Nrf2KO-AL, and
Nrf2KO-CR for both male and female cohorts by one-way ANOVA followed by
Newman’s Keuls post-hoc test. Each letter represents a statistically significant
difference between all groups. For in vitro statistical analysis one-way ANOVA
followed by Dunnett’s Test was performed to determine significant differences
between control (DMSO) and treatments (p<0.05*, p<0.01**, p<0.001***,
p<0.0001****), unless otherwise stated.
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Figure Legends:
Figure 1. ARE and Nrf2-target genes are induced with weight loss via
calorie restriction. ARE-hPAP mice were fed ad libitum (n=4) or 40%
calorically restricted (n=5) for 5 weeks. A) Body weight (g) was monitored
weekly. B) Blood glucose (mg/dL) was measured via tail vein bleed using a
Bayer® glucometer week 2,4 and 5. C) All metabolically active tissues at time
of necropsy were analyzed for mRNA expression via qPCR. Significance was
determined by Student t-tests between AL and CR cohorts (p<0.05*,
p<0.01**).
Figure 2. Mouse ARE and Nrf2-target genes are not transcriptionally
activated in old age. Two cohorts of ARE-hPAP mice were fed either ad
libitum or 40% calorically restricted: mature age mice had an average age of
16 wks±25.5 and old age mice had an average age of 97 wks±16. A) WAT
from mature aged mice (n= ) and B) WAT from old age mice (n= ) were
analyzed for mRNA expression via qPCR. Significance was determined by
Student t-tests between AL and CR cohorts (p<0.05*, p<0.01**, p<0.001***).
Figure 3. Decreased body weight and WAT due to calorie restriction is
not Nrf2-dependent. Both C57Bl/6 and Nrf2KO 16-week old mice were fed
ad libitum or 40% calorically restricted for 5 weeks (males) or 25% calorically
restricted for 6 weeks (females). A) Male and female body weights (g) were
measured weekly. B) At time of necropsy male and female WAT weight was
measured (g, 0.01) and C) mRNA expression of Nrf2 and Nqo1 was measured
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via qPCR. A one-way ANOVA followed by Newman-Keuls post-hoc was used
to determine statistical significance between all groups within each separate
cohort (male and female) (each letter represents a difference in significance,
a-d).
Figure 4. Calorie restriction induces genes involved in antioxidant
response in WAT. Gclc and Catalase, important antioxidant enzymes, were
measured in male and female mice fed ad libitum or calorically restricted
(40%, and 25% CR, respectively) were measured by qPCR. A) Gclc mRNA
expression compared to WT-AL. B) Catalase mRNA expression compared to
WT-AL. Statistical significance was determined by One-way ANOVA followed
by Newman Keuls post-hoc.
Figure 5. Serum total antioxidant capacity in both male and female mice
calorically restricted. Total antioxidant capacity was measured in serum of
both (A) male and (B) female mice fed ad libitum or calorically restricted (40%
and 25%, respectively) by ORAC assay and expressed as Trolox equivalents
(μM) determined from standard curve of Trolox antioxidant capacity.
Statistical significance was determined by one-way ANOVA followed by
Newman Keuls post-hoc.
Figure 6. Nrf2 is not needed for the induction of WAT Sod1 protein and
activity by calorie restriction in female mice. WAT collected from the
female cohort (ad libitum or 25% calorically restricted) was analyzed for mRNA
expression, protein levels, and enzymatic activity of Sod1. A) Sod1 mRNA
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expression by qPCR was normalized to B2M and represented as fold-change
compared to WT-AL B) Sod1 protein was determined in whole cell lysates by
western blot and expressed as RLU normalized to Gapdh C) Sod1 activity was
measured by a commercially available kit (Biovision, Milpitas, CA) and
represented as the % inhibition of xanthine oxidase. The sample absorbance
was normalized to individual sample blanks and % inhibition was calculated
according to kit protocol. Induction of WAT Sod1 may directly contribute to
decreased blood glucose levels, glucose tolerance, and hepatic
gluconeogenesis. Blood glucose concentrations were taken every 2-weeks
and at time of necropsy and glucose tolerance test (GTT) was performed at
week 4 and pyruvate tolerance test (PTT) was performed at week 5 of calorie
restriction. Blood samples were taken via tail vein bleed and glucose
concentrations were measured by a Bayer® glucometer following IACUC
protocol D) Average blood glucose levels (mg/dL) are represented over the
course of the study E) Glucose concentrations were taken prior to i.p. injection
of 2g/kg glucose and 15, 30, 60, and 120 minutes post-injection to measure
glucose tolerance F) Glucose concentrations were taken prior to i.p. injection
of 2g/kg sodium pyruvate and 15, 30, 60, and 120 minutes post-injection to
indirectly measure hepatic gluconeogenesis.
Figure 7. p-Ampk and Pparγ lipid regulation is dysregulated at the
transcriptional and protein level in Nrf2KO mice in vivo altering
transcriptional regulation of lipid uptake genes. WAT from male and
female mice fed ad libitum or calorically restricted were analyzed for mRNA
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expression and protein levels to assess the role of CR and Nrf2 in p-Ampk,
Pparγ, Lpl, and Cd36 expression. A) Transcriptional regulation of Pparγ, Lpl,
and Cd36 was determined by measurement of relative mRNA normalized to
B2M expression, and represented by fold change compared to WT-AL. B) All
proteins were visualized by western blot and quantified using ImageJ analysis.
Quantification of protein was normalized to β-actin levels and expressed as
RLU (n=3). Statistical significance was determined by one-way ANOVA
followed by Newman Keuls post-hoc.
Figure 8. Nrf2-dependent induction of rate-limiting enzyme of lipolysis,
hormone sensitive lipase (Hsl). Hsl gene expression was measured in both
male and female cohorts by qPCR to determine the transcriptional activation
upon CR.
Figure 9. Negative feedback for induction of lipogenic enzymes does not
occur in Nrf2-KO mice, but β-oxidation genes are responsive in both
cohorts. (A) Lipogenic and (B) β-oxidation gene expression was measured in
the female cohort via qPCR and represented as fold change compared to WTAL. (C) Both male and female protein expression of Acc was measured to
confirm transcriptional regulation by Nrf2. Average protein band intensity per
group (n=3) are represented by RLU measurement in ImageJ and normalized
to β-actin expression.
Figure 10. Nrf2 and downstream targets are inducible in cultured
adipocytes resulting in increased antioxidant capacity. 3T3-L1 pre-
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adipocytes were differentiated to mature adipocytes and treated at Day 9 in
the presence of AICAR (500 μM), Oltipraz (100 μM), and Sulforaphane (10
μM) for 24 hr prior to isolation. A) mRNA expression of Nrf2, Nqo1, and Gclc
was measured via qPCR (n=3) as fold change compared to WT-AL B) NEPER extraction was performed to obtain the cellular cytosolic fraction, and an
ORAC assay was performed to measure total antioxidant capacity represented
at Trolox equivalents (μM), determined from a Trolox standard curve. C) pAmpk and Nqo1 protein was measured in whole cell lysate RIPA extractions at
6 hr, 12 hr, and 24 hr to demonstrate time-dependent induction, and are
represented by western blot. Refer to Supplemental figure 3 for quantification
and total AMPK and β-actin protein expression.
Figure 11. Nrf2 inducing agents decrease lipid content and in cultured
adipocytes. Mature 3T3-L1 pre-adipocytes and MEFs were treated with
DMSO (0.1%), AICAR (500 μM), oltipraz (10 μM), sulforaphane (10 μM), and
Sirt1720 (10 μM), Day 8-10 and Day 9-13, respectively. A) Triglyceride
concentration (mg triglyceride/ g protein) was determined following 48 h
treatment and B) total neutral lipid content was visualized by Oil Red O
staining after 24 and 48 h treatments. A Dunnett’s test was used to analyze
significance of treatment compared to control (p<0.05*, p<0.0001****).
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Supplemental Figure 1. Total tissue weights of ARE-hPAP mice fed ad
libitum or CR. WAT and liver tissue were collected at time of necropsy from
ARE-hPAP mice fed ad libitum or 40% CR. Accurate weights (0.00g) were
obtained prior to snap freezing A) Average WAT weight (g) B) Average liver
weight (g). Statistical significance was determined by Student’s T-test,
p<0.001*** p<0.0001****.
Supplemental Figure 2. Primary human mesenteric adipocytes treated with
Ampk and Nrf2 activators demonstrated induced lipolysis ex vivo. Primary
human adipocytes were used to determine if treatment with chemical
activators, used in in vitro CR studies, stimulated lipolysis. Primary human
adipocytes were isolated from the mesenteric depot from an individual donor
and incubated in the presence of adenosine deaminase (ADA, Roche,
Indianapolis, IN), phenylisopropyl adenosine (PIA) and a chemical activator of
Ampk or Nrf2 (n=3/treatment of biological replicates). ADA and PIA are used
to standardize any variations in adenosine levels, and ADA (1 units/mL) + PIA
(20nM) is considered basal lipolytic rate due to inhibition of adenosine.
Positive control, isoproterenol (10-6 M), was performed alongside treatments
for direct measurement of stimulated lipolytic rates. Isoproterenol significantly
stimulated lipolysis with an average glycerol release of 367.6 nM (p<0.0001).
Glycerol release was measured in the presence of AICAR (500 μM), Oltipraz
(100 μM), and Sulforaphane (10 μM) (n=9/treatment—biological replicates
performed in triplicate). Statistical significance was determined by one-way
ANOVA followed by Dunnett’s Test (p<0.01** and p<0.0001****).
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Supplemental Figure 3. Protein expression was measured in 3T3-L1 preadipocytes following 6, 12, and 24 hr exposures. A) p-Ampk:AMPK and
Nqo1 protein quantification via ImageJ (n=1) normalized to β-Actin B) Total
Ampk levels quantified via ImageJ B) β-Actin and total Ampk levels
represented via western blot.
Supplemental Figure 4. Decreased triglyceride content in liver due to
calorie restriction. Overall decrease in liver weights was measured, and the
metabolically active tissue was analyzed for changes in lipid content due to
40% calorie restriction in male and 25% calorie restriction in female cohorts for
5-6 weeks. A) Liver weights were measured at time of necropsy (0.00 g) prior
to snap-freezing of tissue. Lipid extraction was performed on liver PBS lysates
to measure B) triglyceride (mg triglyceride / g tissue) content and C) Serum
triglycerides were measured directly.
Supplemental Figure 5. Average daily calorie intake during calorie restriction
in in vivo models. Male ARE-hPAP and Male WT and Nrf2KO mice were
subjected to a 40% calorically restricted diet. Female WT and Nrf2KO mice
were only subjected to a 25% calorically restricted diet, but their daily caloric
intake was not significantly different from the male cohorts. A) Food intake
was measured by total feed weight consumed and converted into calorie
intake (3.89 kcal/g—purified chow) and represented as average kcal/day. B)
Calorie intake per day during calorie restriction was determined by a 40%
(males) or 25% (females) decrease in average total Kcal/day consumption.

41

Figure I-1.

42

Figure I-2.

43

Figure I-3.

44

Figure I-4.

Figure I-5.

45

Figure I-6.

46

Figure I-7.

47

Figure I-8.

48

Figure I-9
.

49

Figure I-10

.

50

Figure I-11.

51

Supplemental Figure I-1.

Supplemental Figure I-2.

52

Supplemental Figure I-3.

53

Supplemental Figure I-4.

54

Supplemental Figure I-5.

55

MANUSCRIPT II
This manuscript is prepared for submission to the journal Toxicological Sciences
BDE-99 increases lipid accumulation throughout differentiation in 3T3-L1 and
human pre-adipocytes in vitro

Laura E. Armstrong*, Stephen Akinbo*, Mike MacArthur†, and Angela L. Slitt*.
Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island,
Kingston, RI*, Department of Nutrition and Food Sciences, University of Rhode
Island, Kingston, RI†

Abbreviated Title: BDE-99 increases lipids in pre-adipocytes
Corresponding Author:
Angela Slitt, Ph.D.
Department of Biomedical and Pharmaceutical Sciences
7 Greenhouse Rd. Kingston, RI 02881 Fax:
E-mail: aslitt@uri.edu
Word Count:
Abstract: 137 (250)
Intro: 705 (750)
Discussion: 831 (1500)
References: 17
Greyscale Illustrations: 3
Color Illustrations: 4

56

Abstract
Flame retardants, specifically polybrominated diphenyl ethers (PBDEs), are chemical
compounds widely used for industrial purposes and household materials. NHANES
data indicates that nearly all Americans have trace amounts of PBDEs in serum, with
even higher levels associated with occupational exposure (foam recyclers and carpet
installers). PBDEs are known to bioaccumulate in the environment due to their
lipophilicity and stability, and more importantly have been detected in human adipose
tissue. The present study examined whether the PBDE congener, BDE-99 (0.2 μM20 μM) enhances adipogenesis of pre-adipocyte cell models in vitro by increased lipid
accumulation. 3T3-L1 mouse pre-adipocytes and human visceral pre-adipocytes
were analyzed for increased lipid development. The second most abundant
congener found in human adipose tissue, BDE-99 (20 μM), increased chemicallyinduced pre-adipocyte differentiation in both mouse and human in vitro models.
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Introduction
Polybrominated diphenyl ethers (PBDE) are a class of brominated flame retardants
that were part of the largest marketed group of flame retardants in 2004 due to their
effectiveness and low cost (Birnbaum and Staskal, 2004).

There are 209 congeners

of PBDEs, with the most prevalent being BDE-47,-99,-100,-153, and -154 (Birnbaum
and Staskal, 2004). PBDEs are found in electronics, textiles, and polyurethane foam,
with major routes of exposure being inhalation and ingestion through indoor air /dust,
outdoor air, animal food, and aquatic biota world-wide (Hoppe and Carey, 2007).
PentaBDE was a commercially used flame retardant that is predominantly found in
polystyrene foams, accounting for 30% of the weight of the foam, and was essentially
only used in the Americas (Birnbaum and Staskal, 2004). Due to the lipophilic and
highly stable nature of PBDEs, concern has grown over their bioaccumulation in the
environment; as evidenced by their persistence in the environment via air/dust for 2
days, water for 2 months, and soil for 6 months (Birnbaum and Staskal, 2004). A
remarkable decline in PBDE exposure has not been noted since initial bans of use of
pentaBDE in 2008; which, could potentially be due to the persistence of the
compounds in products prior to the ban, new products made from recycled materials,
and continued presence in food sources (Tung et al., 2014). PBDEs are detected in
human adipose tissue, breast milk, birds, mammals, and fish (Hoppe and Carey,
2007), and it is noted in a 2003-2004 study of a cohort in New York City that the BDE47 and BDE-99 were the most prevalent congeners found in human subcutaneous fat
depots with a mean concentration of 399 ng/ g lipid weight (Johnson-Restrepo et al.,
2005). BDE-99 has been shown to be a well absorbed congener, and therefore
preferred sites of deposition are lipophilic tissues (Birnbaum and Staskal, 2004).
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The persistence of PBDEs and their potential effects on the environment and
human health has been brought to the forefront by the US EPA, who identified
PBDEs a priority human health concern (Tung, Boudreau, Wade and Atlas, 2014).
Due to the deposition of the most abundant congeners in WAT (BDE-47 > BDE-99 >
BDE-100 > BDE -153) (Johnson-Restrepo, Kannan, Rapaport and Rodan, 2005) and
the increased knowledge of interactions between persistent organic pollutants
(POPs), predominantly endocrine disruptors, and adipose tissue (AT) (La Merrill et
al., 2013), recent research has begun to focus on the effects of PBDEs on AT
metabolism. It has been well established that PBDEs act as endocrine disruptors by
decreasing T4 levels or identified as agonists/antagonists of estrogen receptors
(Hoppe and Carey, 2007).
AT is metabolically active and essential for normal lipid homeostasis.
Adipocytes can be stimulated by insulin to store excess energy in the form of
triglycerides, and can release those stores by lipolysis to meet energetic needs during
periods of metabolic stress (e.g. fasting and calorie restriction) (La Merrill, Emond,
Kim, Antignac, Le Bizec, Clement, Birnbaum and Barouki, 2013). Due to the nature
of the composition of AT, persistent organic pollutants (POPs) can not only alter
metabolic pathways in mature adipocytes, but can influence the differentiation of preadipocytes. Pre-adipocytes are fibroblasts within WAT that are induced through
hormonal signals and a specific signal-transduction cascade to differentiate (Kamstra
et al., 2014). The study of effects of POPs on the differentiation of pre-adipocytes is
directly relevant to developmental models, insulin sensitivity, and obesity related to
WAT metabolism. Therefore, there are several publications that address BDE-47
effects on pre-adipocyte differentiation (Kamstra, Hruba, Blumberg, Janesick,
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Mandrup, Hamers and Legler, 2014), but none that address the second major
congener BDE-99.
Oral administration of a BDE-47 and BDE-99 mixture to rats altered insulin
signaling with an increase in isoproterenol-stimulated lipolysis and decrease in
insulin-stimulated glucose oxidation that resembled metabolically obese and noninsulin-dependent diabetic individuals (Hoppe and Carey, 2007). Body burden of
other BDEs are also implicated in the pathogenesis of diabetes and metabolic
syndrome (Lim et al., 2008). Therefore, studies using PBDE mixtures and the
predominant congener BDE-47 for effects on adipogenesis have been of recent
interest. The mechanism by which PBDE mixtures enhance adipogenesis in WAT is
not clear, and considering that the most prevalent congeners in human WAT are
BDE-47, BDE-99, and BDE-153 (Johnson-Restrepo, Kannan, Rapaport and Rodan,
2005), this paper focuses on determining the effect and mechanism by which BDE-99
alone can contribute to an enhanced adipogenic effect.
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Materials and Methods
Chemicals and Reagents. A neat 2,2',4,4',5-Pentabromodiphenyl ether preparation
(BDE-99, catalog# ; lot# ) was purchased (AccuStandard®,Inc., New Haven, CT, and
stock solution was prepared to 100 μM in DMSO. Dulbecco's Modified Eagle
Medium (DMEM) high glucose (4.5 g/L) with L-glutamine (Lonza), DMEM/F-12
(Gibco), Fetal Bovine Serum (FBS, Gibco), and penicillin-streptomycin (pen-strep)
was purchased from Thermo Fisher Scientific (Waltham, MA). All other chemicals
were purchased from Sigma-Aldrich (St. Louis, MO): Dimethyl Sulfoxide (DMSO) , 3isobutyl-1-methylxanthine (IBMX), Dexamethasone (DEX), and human insulin
solution, specifically.

3T3-L1 pre-adipocyte cell culture, differentiation, and treatment.

Mouse 3T3-

L1 pre-adipocytes (ATCC® CL-173™) were obtained from American Type Culture
Collection (ATCC, Manassas, VA) and were cultured according to ATCC protocol.
3T3-L1 pre-adipocytes (passage 6) were induced and differentiated according to a
previously described protocol (Shin et al., 2009; Xu et al., 2012). Briefly, 48 h postconfluent cells (day 0) were induced by induction media (DMEM, 10% FBS, IBMX,
DEX, insulin (10 μg/mL)) for 48 h and then differentiated only in the presence of
insulin (10 μg/mL) for 6 days. Initial treatment of cells with vehicle (DMSO) or BDE99 (20 μM) was performed from Day 0-2 (induction) and Day 2-8 (post-induction). All
subsequent experiments, cells were treated with vehicle (DMSO) or BDE-99 (20 μM)
throughout the course of differentiation, Day 0-8, and media was changed every 2
days.
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Human pre-adipocyte cell culture, differentiation, and treatment. PoieticsTM
human visceral pre-adipocytes (Cat #: PT-5005 Lot #: 0000313366, Lonza,
Walkersville, MD) were passaged once and differentiated according to manufacturer’s
instructions for use. Cells were seeded at a density of 8700 cells/well in a 48-well
plate using prepared Preadipocyte Growth Medium-2. Treatment with BDE-99 (20
μM) was carried out in the absence and presence of prepared Adipocyte
Differentiation Medium (prepared media did not contain indomethacin) at day 0 and
cells were stained for lipids or collected for mRNA analysis on day 11.

Oil Red O Staining and Lipid Quantification.

3T3-L1 and human pre-adipocytes

were stained for lipid development (n=3). Cells were stained with Oil Red O at day 4,
day 6, or day 8 following previously published protocol (Armstrong et al.). Oil Red O
images were taken at 10x magnification (EVOS, Life Technologies, Carlsbad, CA),
and Oil Red O staining was quantified by isopropanol (100%) extraction followed by
absorbance measured at 510 nm on Spectramax M2 (Molecular Devices, Sunnyvale,
CA) and ImageJ software (National Institute of Health) following the previous
published protocol (Mehlem et al., 2013).

Western blot.

Western blots were used for identification and quantification of 3T3-

L1 pre-adipocyte proteins from total cell lysates in RIPA buffer. Protein was
electrophoretically separated by SDS-polyacrylamide gel electrophoresis. Primary
antibodies for Fatty Acid Synthase (C20G5) (Fas, #3180, Cell Signaling, Beverly, MA)
and Fatty acid binding protein 4 (D25B3) (Fabp4, #3544, Cell Signaling) were
prepared in 5 % BSA in TBS-T at a 1:3000 dilution and incubated at 4°C overnight.
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Secondary antibody, anti-rabbit (Sigma-Aldrich) was carried out for 1 hr at room
temperature. The blots were incubated in Clarity™ Western ECL Blotting Substrate
(Bio-Rad Laboratories, Hercules, CA) and visualized using autoradiography film.

mRNA expression and quantification of Nrf2. Total RNA was isolated from tissues
or cells using TRIzol reagent (Invitrogen, Carlsbad, CA) following manufacturer
protocol, and quantified following cDNA synthesis (Transcriptor First Strand cDNA
Synthesis Kit) via LightCycler 480® SYBR Green I Master chemistry (Roche Applied
Sciences, Indianapolis, IN). All Nrf2 gene primers were utilized at a final
concentration of 0.5 μM with a final concentration of cDNA template of 50-60 ng.
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Results
BDE-99 induces Fas and Fabp4 during induction (Day 0-2) and post-induction
(Day 2-8) and demonstrated exposure during induction was not needed to
induce lipid accumulation in pre-adipocytes. 3T3-L1 pre-adipocytes were
induced in the presence of hormonal stimulators (DEX, IBMX, and insulin) with and
without BDE-99, and pre-adipocytes were induced and were treated with or without
BDE-99 during insulin-stimulated differentiation. Fas and Fabp4 protein levels were
observed to be induced during induction (Fig 2A), 3.6 and 6.6-fold, respectively
(Supplemental Figure 1). Only Fas was significantly induced (1.5-fold), by postinduction treatment with BDE-99 (Fig. 2A and Supplemental Figure 1). Increased
Fabp4 protein during induction could signify increased fatty acid content prior to
differentiation. Quantification of western blots via ImageJ is shown in Supplemental
Figure 1. Post-induction BDE-99 treatment, in the presence of insulin, stimulated
increased lipid development without chemical exposure during hormonal induction
(Fig 2B and 2C), suggesting a direct involvement in the regulation of WAT
lipogenesis.
BDE-99 increases lipid development in differentiating pre-adipocytes. 3T3-L1
pre-adipocytes were differentiated to mature adipocytes with or without BDE-99 for 6
and 8 days. Oil red O staining was utilized to assess lipid accumulation in maturing
adipocytes. Figure 3A, demonstrates that BDE-99 increases lipid content during
differentiation compared to vehicle (DMSO), and when quantified both day 6 and 8
have a significant increase in Oil Red O staining (Figure 3B). An increase in lipid
staining compared to DMSO was similar in both 2 and 20 μM treatments (Figure 4A).
Quantification of the dose-dependent changes in lipid development revealed
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increased in lipid staining for cells treated with 2 and 20 μM BDE-99, but not 0.2 μM.
The induction was not concentration dependent (Figure 4B).
BDE-99 treatment increases lipid development in human visceral preadipocytes during differentiation. In order to determine whether BDE-99 also has
effects in human derived-cells we determined whether BDE-99 treatment increased
lipid development using human visceral pre-adipocytes. Human visceral preadipocytes (Lonza) were treated with vehicle or BDE-99 (20 μM) in the absence or
presence of differentiation media. Figure 5A illustrates that lipid development is
enhanced in both non-differentiated and differentiated pre-adipocytes, as depicted by
an increase in Oil Red O staining with BDE-99 treatment compared to DMSO.
Staining was quantified by Oil Red O absorbance and a significant increase of
staining was shown in both non-differentiated and differentiated cells (Figure 5B);
staining was further confirmed by ImageJ quantification of images of Oil Red O
staining in which differentiated cells had a 1.9-fold increase and non-differentiated
cells had a greater 2.7-fold increase in total lipid content (Figure 5C).
BDE-99 decreases Nrf2 expression during adipogenesis. Nrf2 gene expression is
increased throughout the course of adipocyte differentiation, and BDE-99 (20 μM)
decreases the basal level expression of Nrf2 throughout the course of differentiation
(Figure 6). Therefore, BDE-99 may not be acting directly on key pathways of
adipogenesis, but may alter expression of Nrf2 that has previously shown to be
important in adipocyte differentiation in mouse embryonic fibroblasts (Pi et al., 2010).

65

Discussion
PBDEs have been identified as a primary human health concern by the U.S.
EPA. PBDEs have been shown to have toxicity potential in in vivo models, including
altered thyroid hormone levels and morphological effects in thyroid, liver and kidney
(Kalantzi et al., 2011), and non-Hodgkin’s lymphoma (Kalantzi, Geens, Covaci and
Siskos, 2011) and metabolic syndrome (Lim, Lee and Jacobs, 2008) have been
associated with PBDE exposure in humans. These observations are even more
concerning, as measurements of PBDE levels were assessed in the human
population over the last decade (Johnson-Restrepo, Kannan, Rapaport and Rodan,
2005; Malarvannan et al., 2013; Sjodin et al., 2008; Stapleton et al., 2008) with
increasing exposures noted and persistence/bioaccumulation of compounds in the
environment (Birnbaum and Staskal, 2004). Human levels of PBDEs and specific
congeners are not consistent across all studies. PBDE exposure differs between
populations, specifically concentrations of PBDEs in human matrices of European
populations, exhibited lower exposure levels than U.S. populations predominantly due
to the decreased usage of BFRs in these countries (Malarvannan, Dirinck, Dirtu,
Pereira-Fernandes, Neels, Jorens, Gaal, Blust and Covaci, 2013). Not only do
exposure levels differ, but U.S. populations have demonstrated a difference in
distribution of PBDE congeners (Kalantzi, Geens, Covaci and Siskos, 2011).
PentaBDE is a mixture that is predominantly used in the United States and is
composed primarily of tri- and hepta-BDEs(Kalantzi, Geens, Covaci and Siskos,
2011); therefore, research within the U.S. has focused on congeners BDE-47 and
BDE-99 due to population and environmental levels. Our findings utilizing BDE-99
predominately represent exposure specific to the U.S. population by exposure to
pentaBDE (Kalantzi, Geens, Covaci and Siskos, 2011).
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BDE-47 has been demonstrated to induce adipogenesis in models of 3T3-L1
pre-adipocyte differentiation (Kamstra, Hruba, Blumberg, Janesick, Mandrup, Hamers
and Legler, 2014; Tung, Boudreau, Wade and Atlas, 2014), but the mechanism of
action of BDEs needs to be studied further. A mixture of PBDEs representative of the
North American body burden and BDE-47 alone were shown to have dose-dependent
increased in aP2 and perilipin protein and significant increase in mRNA expression by
day 8, which is representative of increased lipid droplet size and development
demonstrated through increased lipid accumulation by both treatments (Tung,
Boudreau, Wade and Atlas, 2014). This supports our observations that the congener
BDE-99 also contributes to increased lipid development in differentiating preadipocytes. The findings also demonstrate that exposure during initial induction of
pre-adipocytes is not needed to increase total lipid staining, as was previously shown
with modest changes to mRNA expression during the first 2 days of differentiation
(Kamstra, Hruba, Blumberg, Janesick, Mandrup, Hamers and Legler, 2014).
An interesting finding and contribution to understanding the mechanism of
BDE-induced adipocyte differentiation and lipid accumulation was BDE-47 and BDE99 have poor Pparγ binding activity determined by their relative potency (determined
from IC50 and Kd values) (Fang et al., 2015). The only active ligands of Pparγ were
hydroxylated metabolites of BDE-47, and 5-OH-BDE-99 (Kd=30 μM)(Fang, Webster,
Ferguson and Stapleton, 2015). Therefore, no significant induction of Pparγ
transcript by BDE-47 (Tung, Boudreau, Wade and Atlas, 2014), and induction of
Pparγ2 mRNA without down-stream target gene expression (Kamstra, Hruba,
Blumberg, Janesick, Mandrup, Hamers and Legler, 2014) in 3T3-L1 cells
demonstrates that Pparγ activation may not be the predominant transcription factor
involved in induction of lipid development. Preliminary studies of Pparγ protein
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expression showed that the transcription factor was not up-regulated in our exposure
model, but the γ2-subunit was induced with treatment without Cepbα induction
(Supplemental Figure 2). Interestingly, Pparγ expression was significantly increased
by Day 8 by a PBDE mixture (Tung, Boudreau, Wade and Atlas, 2014), suggesting
other potential congeners or metabolites are involved in its regulation. Our
subsequent finding of decreased Nrf2 expression with BDE-99 treatment supports a
potential hypothesis of decreased adipogenesis with increased lipid development,
resulting in hypertrophic adipocyte development. It has previously been
demonstrated that Nrf2KO MEFs have decreased ability to differentiate (Pi, Leung,
Xue, Wang, Hou, Liu, Yehuda-Shnaidman, Lee, Lau, Kurtz and Chan, 2010), and
without Pparγ and Cebpα induction, BDE-99 does not contribute to increased
differentiation. Therefore, further studies must be carried out to determine what
lipogeneic pathway is targeted by BDE-99 treatment to increase lipid development
throughout differentiation.
BDE-99 was studied due to its prevalence in human adipose tissue, and more
specifically because of its defined metabolism and disposition in rat and mouse
models (Chen et al., 2006). Chen et al. demonstrated that 85% of BDE-99 was
absorbed by single-p.o. and 34-38% remained in tissues, with significant disposition
in adipose and minimal decay of levels over 10 days, and significant increase in
concentration with 10-day daily doses (Chen, Lebetkin, Sanders and Burka, 2006). In
addition to concentrated exposure of BDE-99 exposure in adipose tissue, it was
demonstrated that BDE-99 was also more extensively metabolized than BDE-47,
which is excreted by day 10 (Chen, Lebetkin, Sanders and Burka, 2006). Therefore,
the effect of BDE-99 exposure on adipose tissue is an essential to understand
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potential human health outcomes, in which BDE-99 metabolites may need to be
addressed for their toxicity also.
Our study is the first to translate BDE-99 effect on adipogenesis and lipid
development to a human model. The findings support that human pre-adipocytes
develop increased lipid development upon BDE-99 exposure in both nondifferentiated cells, and differentiating cells. This research provides additional data
supporting the understanding of POP exposure to cause dysregulation of insulin
homeostasis, obesity, and hepatic steatosis,(Ruzzin et al., 2010) and the toxicological
importance of adipose tissue (La Merrill, Emond, Kim, Antignac, Le Bizec, Clement,
Birnbaum and Barouki, 2013). Therefore, these human in vitro data can be utilized in
order to determine if increased BDE-99 concentrations in adipose tissue contribute to
insulin resistance, diabetes, obesity, and overall metabolic syndrome, with a
mechanistic approach.
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Figure 1. In vitro pre-adipocyte differentiation paradigm with treatment of
environmental toxicant BDE-99.
Figure 2. BDE-99 induces Fas and Fabp4 during induction (Day 0-2) and postinduction (Day 2-8) and it was demonstrated that exposure during induction of
pre-adipocytes was not needed to induce lipid accumulation. 3T3-L1 preadipocytes were treated with BDE-99 (20 μM) during induction (Day 0-2) and postinduction (Day 2-8). A) Induced and post-induction pre-adipocytes treated with BDE99 were lysed in RIPA buffer and Fas and Fabp4 protein levels were determined by
western blot B) Post-induced pre-adipocytes were stained with Oil Red O, images
were taken at 10x magnification C) Images were quantified using ImageJ to
determine induction of lipid content (n=2/treatment).
Figure 3. Increased lipid development throughout differentiation of 3T3-L1 preadipocytes treated with BDE-99. 3T3-L1 cells were differentiated in the presence of
DMSO (0.1%, control) or BDE-99 (20 μM). A) Treated 3T3-L1 cells were stained for
the development of neutral lipids by Oil Red O at Day 6 and Day 8. B) BDE-99
dependent lipid development was determined through quantification of 5 separate Oil
Red O images taken at 10x magnification per well (n=3 wells/treatment group).
Significance was determined by individual Student’s t-test compared to control at
each time point (p<0.01**, p<0.0001****).
Figure 4. Lower doses of BDE-99 in vitro elicit the same enhancement of lipid
development in 3T3-L1 pre-adipocytes. 3T3-L1 cells were differentiated in the
presence of DMSO (0.1%, control) or BDE-99 (0.2, 2, or 20 μM). A) Treated 3T3-L1
cells were stained with Oil Red O at Day 8. B) Enhancement of lipid development
during differentiation was quantified by ImageJ utilizing 5 separate Oil Red O images
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taken at 10x magnification per well (n=3 wells/treatment group). A Dunnett’s test was
used to determined significance compared to control (p<0.01**, p<0.001***).
Figure 5. Human visceral pre-adipocytes responded to BDE-99 treatment
equally, with increased lipid content in mature adipocytes. Human visceral preadipocytes were treated with BDE-99 (20 μM) with and without Adipocyte
Differentiation Media (ADM) for 11 days. A) Cells were stained with Oil Red O on
Day 11 for the accumulation of neutral lipids in matured adipocytes and images were
taken at 10x, 20x (not shown), and 40x magnification (EVOS, Life Technologies). B)
Oil Red O was abstracted from the fixed cells with 100% isopropanol, and
absorbance of each well was measured at 510 nm to quantify lipid staining. C)
ImageJ software was utilized to quantify 5 images from each well (n=3
wells/treatment group) to confirm quantification of Oil Red O staining. Significance
was determined by Student’s t-test compared to control for both non-differentiated
and differentiated staining (p<0.05*, p<0.01**).
Figure 6. BDE-99 decreases transcriptional expression of Nrf2 throughout
differentiation. 3T3-L1 cells were treated with DMSO (0.1%, control) or BDE-99

(20 μM) from Day 0 to Day 8 of differentiation, and total RNA was collected at
Day 4, Day 6, and Day 8. Nrf2 mRNA expression was quantified via qPCR
and normalized to housekeeping gene B2M. Student’s T-test was used to
determine the statistical significance between treatments for each individual
time point (p<0.05*).
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Supplemental Figure 1. Quantification of Fas and Fabp4. Fas and Fabp4
were measured to assess the lipogenic pathway in BDE-99-treated 3T3-L1
cells and fatty acid content. Band intensity of each protein was measured via
ImageJ (n=1). Fas and Fabp4 protein was normalized to β-Actin, and
expressed as Relative Luminescence Units (RLU).
Supplemental Figure 2. Protein detection of adipogenic transcription
factors in BDE-99-treated 3T3-L1 cells. 3T3-L1 cells were exposed to 20
μM BDE-99 during day 0-2 and day 2-8 of adipocyte differentiation, and whole
cell lysates were obtained via RIPA extraction. A) Western blots of Pparγ and
Cebpα.
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Figure II-1.
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Figure II-2.
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Figure II-3.
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ABSTRACT
Deltamethrin, a type II pyrethroid, is a widely used insecticide. The purpose of
this study was to determine whether perinatal deltamethrin exposure altered
the expression of adipogenic and lipogenic genes in white adipose tissue
(WAT) in adult pups. C57BL/6 pregnant mice were administered 0, 1, or 3
mg/kg of deltamethrin orally every 3 days throughout gestation and lactation.
Offspring were weaned on postnatal day 25 and WAT was collected from 5
month old male mice. Perinatal deltamethrin exposure decreased the mRNA
expression of adipogenesis related transcription factors Pparγ, Cebpα and
lipogenic genes Srebp1c, Acc-1, Cd36, Lpl, Scd-1; along with Nrf2 and target
genes Nqo1 and Gclc at the 1 mg/kg treatment.

Cytokine expression of

Fas/Tnf-R and Cd209e at the 1 mg/kg treatment was significantly decreased
and expression of Tnf, Cd11c, and Fas/Tnf-R was decreased at the 3 mg/kg
treatment. Developmental deltamethrin exposure did not overtly affect body
weight or adipose weight, but decreased mRNA expression of specific genes
that may potentially disrupt normal adipogenesis and lipid and glucose
metabolism if the offspring are challenged by changes in diet or environment.
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INTRODUCTION
Pyrethroids are synthetic chemicals modeled after the naturally
occurring pyrethrins, found in chrysanthemums (1).

Type I and type II

pyrethroids are commonly used as potent and effective insecticides for
agricultural and public health applications (2) and can easily enter the
exoskeleton of insects. These axonic poisons cause paralysis, and ultimately
death of the organism by keeping sodium channels open in the neuronal
membranes. Type II pyrethroids, such as deltamethrin, are defined by an αcyano group that is known to produce a longer-lasting inhibition of voltageactivated sodium channels (1,2). Pyrethroid pesticides are often thought of as
“safer” alternatives to the more toxic organophosphates because of their low
mammalian toxicity. This relatively low toxicity is attributed to a combination of
efficient detoxification mechanisms in mammals (3) and lower sensitivity of ion
channels (2). However, metabolic detoxification mechanisms are not fully
developed in the very young, potentially increasing susceptibility to pyrethroids
in this population (4). This is particularly crucial because pyrethroid use has
increased tremendously since the cancellation or reduction in the use of many
organophosphorus pesticides (5).

In recent years, significant levels of

pyrethroid metabolites, including those of deltamethrin, have been found in the
urine of pregnant women and children (6-9). Furthermore, deltamethrin, which
is widely used to control malaria vectors, has also been detected in the breast
milk of South African women (10). The latter data pose questions regarding
the safety of deltamethrin, as developmental neurotoxicity and other adverse
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developmental effects are currently being studied in these susceptible
populations (1).
Adipose tissue is a lipophilic tissue that is metabolically active and
essential

for

the

proper

maintenance

of

systemic

energy

balance.

Adipogenesis requires a highly regulated cascade of transcription factors,
including C/EBP family and Pparγ, which regulate the differentiation of
preadipocytes to adipocytes (11). Most recently, this cascade of transcription
factors has been proven to be regulated by Nrf2, a well-defined transcription
factor of oxidative stress (12,13). The three major functions of adipose tissue
are lipid storage and mobilization, glucose homeostasis, and endocrine
function, involving secretion of hormones, cytokines, and transcription factors
(11,14).

Changes in the expression of transcription factors involved in

adipocyte differentiation during development can lead to dysfunction in the
metabolic and endocrine functions of white adipose tissue (WAT), as
demonstrated by gene knock-down, knock-out, and induction studies (11,14).
When characterizing deltamethrin as a safe pesticide, The World Health
Organization (WHO) observed lower body weight gain in adult rats that were
orally administered the pesticide, decreased mean fetal weights with a
perinatal high dose of 10 mg/kg body weight, and a dose-related decrease in
body weight of postnatal mice (15).

Despite increased research on the

developmental toxicology of pyrethroids, to our knowledge, no studies have
addressed whether exposure to pyrethroids during developmental stages
affects adipose tissue development and homeostasis. Therefore, the purpose
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of this study was to address the potential metabolic effects of perinatal
deltamethrin exposure in white adipose tissue, to address previously
described changes in body weight during development.

MATERIALS AND METHODS
Animals
Eight week old female and male C57BL/6J mice purchased from
Jackson Laboratory (Bar Harbor, ME) were used. Mice were maintained on a
12:12 light/dark cycle with food and water available ad libitum. All procedures
were conducted in accordance with the NIH Guide for Care and Use of
Laboratory Animals and approved by the Institutional Animal Care and Use
Committee at Robert Wood Johnson Medical School.
Treatment
10 week old female C57BL/6J mice were individually housed and
mated with C57BL/6J males. Upon identification of a vaginal plug, males were
removed and single-housed female mice were administered 0 (control), 1, or 3
mg/kg body weight deltamethrin (ChemService, West Chester, PA), dissolved
in corn oil and mixed with peanut butter (~ 100 mg; Skippy Creamy Peanut
Butter) every 3 days throughout gestation and lactation as described
previously (16-18). Mice were monitored to ensure total consumption of the
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treatment dose, which generally occurred within 10 min. This administration
method reduces handling stress associated with injections during pregnancy
and most closely mimics human oral exposure conditions (16,17).
The dose selected in this study is 1/4 of the developmental NOAEL
(19).

Unfortunately, the rapid metabolism of pyrethroids has made dose

extrapolation difficult. There have been no comparative studies in rodent and
humans to determine half-lives of the parent compound, but separate studies
have presented the half-life of deltmethrin, in humans and rats, to appear to be
in a similar range of several hours.

It should be noted that recent

pharmacokinetic modeling in rats predicted that humans would experience a
higher brain concentration of deltamethrin compared to rodents, most likely
because humans do not have plasma carboxylesterase activity (20).
The offspring were weaned at postnatal day (PND) 25, and once
weaned; offspring received no additional exposure to deltamethrin.

The 5

month time point was selected because tissues were being shared from a
cohort from a study being conducted by Dr. Richardson’s group for the primary
purpose of developmental deltamethrin effects on behavior. Those cohorts
had been assessed for neurobehavioral changes and 5 months was
determined to be an appropriate time of necropsy for Dr. Richardson’s study.
As 5 months represents adulthood and mature adipose tissue, white adipose
tissue was evaluated for changes in expression of genes related to
adipogenesis, lipid synthesis, glucose uptake, and inflammation.
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Prior to sacrifice, blood glucose concentrations were obtained via tail
vein nick and measured using a TRUEtrackTM glucometer. Animals were not
fasted prior to sacrifice. Mice were sacrificed by CO2 inhalation followed by
cardiac puncture for blood collection at 5 months of age. Blood was
centrifuged at 14,000 × g for 10 min to obtain serum. White adipose tissue
from the abdomen was removed and snap frozen in liquid nitrogen. Samples
were stored at -80oC until shipment to University of Rhode Island on dry ice.
Dosing of mice and sample collection was carried out by the laboratory of Dr.
Jason Richardson at the University of Medicine and Dentistry of New Jersey,
Piscataway, NJ.
RNA Extraction
Perinatal exposure to deltamethrin causes postnatal behavioral
changes in adult male, but not female, offspring (Richardson et al., submitted).
For this reason, adult male mice were selected for the current investigation.
Total RNA was isolated from 50-100 mg frozen WAT from the male 5 month
cohort via homogenization in TrizolTM lysis buffer (Life Technologies, Grand
Island, NY) followed by chloroform-isopropanol extraction. The RNA
concentration was determined by measuring UV absorbance of the sample at
260 nm using NanoDrop™ (Wilmington, DE) and RNA integrity was confirmed
by the presence of distinct 18S and 28S bands using formaldehyde-agarose
gel electrophoresis. RNA samples were stored at -80°C until utilized.
Quantigene Plex 2.0 Assay
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Total RNA was applied to the Quantigene Plex (Affymetrix, Santa Clara,
CA) and hybridized overnight at 54˚C with specific mRNA capture beads and
capture probes. The following day, the samples were hybridized with preamplifier and a biotinylated label probe for 1 h at 50˚C followed by application
of streptavidin conjugated phycoerythrin detection probe for 30 min at room
temperature. The plex was analyzed on a Luminex Bio-Plex 200 array reader
with Luminex 100 xMAP technology (Austin, TX). mRNA expression was
normalized to the Rpl13a housekeeping gene, which was not significantly
different between treatment groups. Only male gene expression in adipose
tissue was determined in an attempt to reduce gender variability as a
confounding factor

qPCR mRNA Quantification
qPCR was utilized measure the mRNA gene expression of important
genes in WAT that were not available on the Quantigene Plex used. Total
RNA was utilized as a template to make complementary DNA via polymerase
chain reaction (PCR) following the specified protocol for Transcriptor First
Strand cDNA Synthesis Kit (Roche Applied Sciences Cat. #: 04897030001).
The cDNA was amplified and quantified for gene expression levels using
LightCycler 480® SYBR Green I Master chemistry (Roche Applied Sciences)
for qPCR determination of Nrf2, Nqo1, and Gclc. Rpl13a was used as the
housekeeping gene for normalization.
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Statistical Analysis
Statistical analyses of data were performed using a one-way analysis of
variance (ANOVA) and further analyzed by a Dunnett’s Test post hoc test to
determine significant different between control and each treatment group. P <
0.05 was considered statistically significant. Unless otherwise stated, all data
were presented as mean ± SE of 9 animals (control) and 8 animals (1 mg/kg,
3mg/kg doses). Statistica v.9 (StatSoft, Tulsa, OK) was used for statistical
analysis.
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RESULTS

Effect of developmental exposure on physiological parameters and the
expression of genes related to glucose homeostasis in WAT
The physiological data collected prior to necropsy showed no significant
differences in the body weight (BW) between pups that were exposed to
vehicle or deltamethrin during development (Fig. 1A), and blood glucose
concentration was similar between both treatments compared to control (Fig.
1B).

The expression of a predominant insulin-responsive gene and two

essential glucose transporters in WAT were determined using Luminex
100xMAP technology.

Figure 1C shows that there were some differences

between the gene expression of insulin responsive genes and glucose
transport genes, Irs-1, Glut4, and Glut2, in WAT. Developmental deltamethrin
(1 mg/kg) exposure decreased Glut4 (31%), and both deltamethrin doses
significantly decreased Glut2 mRNA (83%, 82%). No changes in Irs-1 mRNA
expression were observed. These data are supported by the blood glucose
measurements that were also found to be unchanged with perinatal
deltamethrin exposure.
Effect of developmental deltamethrin exposure on expression of genes
related to adipogenesis and lipogenesis in WAT
There were no significant differences in body weight between the male
pups that were exposed to vehicle or deltamethrin during development at 5
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months of age (Fig 1A), but because of the significant decrease in mRNA
expression in glucose transport the primary functions of adipose tissue,
development of adipocytes and lipid transport and metabolism should be
described.

Expression levels of lipogeneic genes in WAT and the well

described regulators of adipogenesis were determined using Luminex
100xMAP technology. Significant decreases in the expression of lipogenic
genes Srebpf1 (28%), Acc-1 (44%), Fabp4 (19%), Cd36 (21%), Lpl (22%), and
Scd-1 (22%) were observed in the 1mg/kg treatment group compared to
control. Furthermore, no changes in the expression of any of the lipogeneic
genes measured were observed in the 3 mg/kg treatment group (Fig. 2A). The
relative gene expression of adipogenesis regulators (Pparγ, Cebpα, and
Cebpβ) is illustrated in Figure 2B. Perinatal deltamethrin exposure (1 mg/kg)
decreased Pparγ and Cebpα expression in WAT 28% and 32%, respectively,
compared to vehicle controls. Cebpβ expression in WAT was similar for all
groups.

A potential further up-stream regulator of adipogenesis and lipid

metabolism in adipose issue is Nrf2 (13,21). Nrf2 and its target genes Nqo1
and Gclc were measured by qPCR, using LightCycler 480® SYBR Green
chemistry and instrumentation, and presented in Figure 2C. Nrf2, Nqo1, and
Gclc were all significantly down-regulated at the 1 mg/kg treatment. Nrf2 was
decreased to 27%, Nqo1 13%, and Gclc 11% of the control. The decreased
mRNA of the down-stream target genes of Nrf2 suggests the decreased
protein level or activity of Nrf2, which if decreased could potentially explain the
down-regulation of gene expression by perinatal deltamethrin exposure.
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Effect of developmental deltamethrin exposure on cytokine mRNA
expression in WAT
Tnf, Ccl-2, Cd11c, Fas/Tnf-R, Cd209e, and Il4 cytokine levels in WAT
were measured in 5 month old male pups that were exposed to deltamethrin
via perinatal exposure. Significant decreases in cytokine levels for both
treatment groups were observed when compared to control group (Fig. 3). Tnf
levels decreased 47% in the 3 mg/kg treatment group, compared to the control
group. Tnf expression was similar between control pups and pups exposed to
the 1 mg/kg developmental deltamethrin dose. Cd11c expression was only
decreased in the 3 mg/kg group by 66% compared to control. Tnf-R
expression was markedly decreased 70% (1 mg deltamethrin/kg) and 75% (3
mg deltamethrin/kg) when compared to the control group.

Cd209e levels

were decreased to 39% of control in the 1 mg/kg treatment group, but were
similar to controls in the 3 mg deltamethrin/kg group.

There were no

significant differences in Ccl-2 and Il4 cytokine levels compared to the control
in either the 1 mg/kg or 3 mg/kg treatment groups.
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DISCUSSION
Deltamethrin and other pyrethroids have been established as safe
pesticides based on data showing decreased toxicity in mammals from rapid
metabolism to non-toxic or less-toxic forms of the parent compound (3). Many
pharmacokinetic and dynamic studies have elucidated that a portion of orally
administered pyrethroids partition into fatty tissues, in which they persist for at
least 3 weeks (3,22,23). Deltamethrin can be detected in the adipose tissue
of rats with a half-life of 5-6 days (24), and is most persistent in the body fat of
animal models (3).

The retention of these highly lipophilic pesticides in

metabolically active adipose tissue should increase the spectrum of research
from not only neurotoxicity, but to the possibility of metabolic effects of
pyrethroid exposure, especially in susceptible populations.

In this study, we

showed that developmental deltamethrin affects adipogenesis and lipid
homeostasis at the transcriptional level, decreasing the expression of some
genes in the offspring of dams exposed to 1 mg/kg every three days. Previous
toxicological studies noted non-dose-dependent reduction in body weight gain
in adult rats and dogs following short-term exposure (0.1-10 mg/kg), and
decreased fetal weight in rabbits at 16 mg/kg perinatal exposure (15). In a
reproductive study on deltamethrin using rats, Abdel-Khalik et al. (25)
observed a significant dose-dependent difference (p<0.01) in mean fetal
weights and retardation of fetal growth at all doses tested (1, 2.5, 5 mg/kg).
These observations of retarded development of body mass correlate to the
transcriptional down-regulation in gene expression for the major transcription
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factors of adipogenesis, Pparγ and Cebpα, which regulate adipocyte
development and maintain adipocyte phenotype through regulation of
downstream targets Cd36, Lpl, and Glut4. A significant down-regulation of
cytokines excreted by WAT that are involved directly in the T-cell response
(Tnf, Fas/Tnf-R, Cd209e), has a direct influence on the development of
adipocytes. Decreased levels of these cytokines, potentially may contribute to
an altered primary immune response of dendritic cells (Cd209e), initiation of
programmed cell-death by recruitment of caspase (Fas/Tnf-R), or alteration of
macrophage Tnfα secretion, which could impact adipocyte differentiation and
proliferation. The expression of fatty-acid uptake genes, Fabp4, Cd36, and Lpl,
regulated by Pparγ, were down-regulated, consistent with an overall metabolic
change in gene expression for the pathway. The down-regulation of Srebp1c,
a transcription factor abundant in WAT that regulates and maintains lipid
homeostasis through downstream targets Acc-1 and Scd-1, contributes further
to alterations in the metabolic state of WAT in the developing mice.

The

reported non-monotonic dose-response of changes in gene expression cannot
be explained by previous observations or our physiological findings.
The physiological data herein describing cohorts of developmentally
exposed

male

mice

conflicts

with

previously

reported

toxicological

observations for reproductive and developmental toxicity studies in rats, which
reported significant changes in body weight and WAT mass (15).

No

significant difference in body weight and liver weight was observed between
vehicle and deltamethrin-treated groups in multiple cohorts of 4, 5, and 11-12
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months of age male mice (data not shown).

However, the finding that

developmental deltamethrin exposure increases locomotor activity may
confound the interpretation of potential body weight changes and metabolic
phenotypic changes (Richardson et al., personal communication), which is
why the significant changes in regulators of adipogenesis and lipid metabolism
at the mRNA level suggests potential underlying epigenetic effects.
Little is known regarding the effect of deltamethrin on glucose
homeostasis, metabolic, or immune response.

Our data suggest that

developmental deltamethrin exposure had no marked effect on glucose
homeostasis based on blood glucose concentrations, but significant changes
in the relative gene expression of Glut4 and Glut2 in WAT are noted. Glut4 is
a major glucose transporter in WAT that if down-regulated will decrease the
insulin-responsive uptake of glucose into the cells, but the significant downregulation of Glut2 at both treatment doses, major glucose transporter in the
liver, has the potential to affect glucose transport between adipose tissue,
plasma, and potentially liver. A decrease in the glucose transport genes may
alter the deposition of glucose. Early insulin-resistance has been linked to
adipose tissue dysfunction (26) and decreased WAT expandability is
associated with increased risk for diabetes or glucose intolerance (21,27,28).
Thus, deltamethrin might affect the normal response to high-fat diet challenge
or treatment with thiazolidinedones, which promote adipogenesis to improve
insulin resistance.
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The transcriptional down-regulation of genes essential for adipose
development and lipid metabolism in offspring after perinatal exposure to 1
mg/kg dose of deltamethrin provides data that supports the potential for
metabolic effects of deltamethrin exposure during development with regard to
WAT expandability. Nrf2, normally known for its role in oxidative stress, has
recently been shown to be a regulator of adipose development and function
(12). Nrf2 has been shown to be an upstream regulator of Pparγ and Cebpα,
in which Nrf2 knock-out in MEF cells decreased lipid accumulation, decreased
Pparγ and Cebpα expression at the protein, along with down-stream target
genes (13). Therefore, the decreased expression of Nrf2 and its target genes
at the mRNA level can serve as initial evidence that Nrf2 may be involved in
the gene expression changes related most specifically to the transcription
factors Pparγ and Cebpα, and therefore, lead to changes in glucose and lipid
homeostasis.

These significant changes in gene expression at the

transcriptional level may correlate to an epigenetic regulation in the offspring
that may eventually lead to altered responses of WAT to environmental
toxicants (i.e. obesogens, endocrine disruptors) or changes in diet (i.e. high-fat
diet), however these changes did not manifest in significant alteration in
physiological parameters. To summarize, perinatal deltamethrin exposure did
not result in measurable changes in body weight in male offspring at 5 months
of age, but did decrease the expression of some genes related to
adipogenesis, lipogenesis, and inflammation in WAT that may potentially be
under the regulation of alterations in Nrf2 activity.
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FIGURE LEGENDS
Figure 1.

Body weight was used to describe any potential metabolic effects of

perinatal deltamethrin exposure, along with blood glucose concentration and mRNA
gene expression of key factors in insulin response of WAT to describe potential
effects on glucose homeostasis. Body weights of 5 month old male mice were taken
prior to sacrifice. (A) Average body weight (g) of each treatment group expressed as
a mean BW ± SEM (n=6-7). (B) Blood glucose level taken at time of necropsy of 5
mo. adult male mice expressed as a mean BG ± SEM (n=5-6).

mRNA gene

expression data in white adipose tissue of 5 month old adult male mouse pups from
dams exposed to 0, 1, or 3 mg delatmethrin/kg every three days during getation and
lactation. Total RNA was isolated from white adipose tissue and mRNA levels were
quantified by Quantigene Plex 2.0 assay (Affymetrix). All gene expression data were
normalized to Rpl13a (no significant change in gene expression) and are expressed
as mean ± SEM (n=8-9). (A) Insulin responsive and glucose transport: Irs-1, Glut-4,
Glut-2 mRNA expression. mRNA gene expression data in white adipose tissue of 5
month old adult male mouse pups from dams exposed to 0, 1, or 3 mg
deltamethrin/kg every three days during gestation and lactation. * and # represents
statistical difference between control and treatment doses (p<0.05 and p<0.005,
respectively).
Figure 2. mRNA gene expression data in white adipose tissue of 5 month old adult
male mouse pups from dams exposed to 0, 1, or 3 mg deltamethrin/kg every three
days during gestation and lactation. Total RNA was isolated from white adipose
tissue and mRNA levels were quantified by Quantigene Plex 2.0 assay (Affymetrix).
All gene expression data were normalized to Rpl13a (no significant change in gene
expression) and are expressed as mean ± SEM (n=8-9). (A) Regulators of
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B)
genes:Srebp1, Acc-1, Fabp4, Cd36, Lpl, Scd-1 mRNA expression.

Lipogenic

mRNA gene

expression for Nrf2, Nqo1, and Gclc was quantified by Lightcycler 480 SYBR green
qPCR method. (C) Nrf and target genes Nqo1 and Gclc mRNA expression. *and #
represents statistical difference between control and treatment doses (p<0.05 and
p<0.005, respectively).
Figure 3. mRNA gene expression of relevant cytokines in white adipose tissue of 5
month old adult male pups from dams exposed to 0, 1, or 3 mg deltamethrin/kg every
three days during gestation and lactation. Total RNA was isolated from white adipose
tissue and mRNA levels were quantified by Quantigene Plex 2.0 assay (Affymetrix).
All gene expression data were normalized to Rpl13a (no significant change in gene
expression) and are expressed as mean ± SEM (n=8-9) Cytokines: Tnf, Ccl-2, Cd11c,
Fas/Tnf-R (M1 macrophage markers) and Cd209e (M2 macrophage marker). * and #
represents statistical difference between control and treatment doses (p<0.05 and
p<0.005, respectively).
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Figure III-1.
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Figure III-2.
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Figure III-3.
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CONCLUSION
Obesity has previously been defined at the dysregulation of energy balance, in
which nutrient intake exceeds energy expenditure; therefore excess nutrients
are stored in WAT (Christodoulides et al., 2009). The primary role of WAT is
to store excess FFAs in the form of triglycerides, and because of this WAT is
physiologically able to handle greater FFA and oxidative stress loads than
other metabolically active tissues (Kusminski and Scherer, 2012). Therefore,
WAT is known for its expandability—which has been suggested to be directly
related to the pathophysiology of diseases related to overall metabolic
syndrome (Christodoulides, Lagathu, Sethi and Vidal-Puig, 2009). AT
expandability is recognized as an adaptive response to excess nutrient intake,
thus preventing lipid deposition and toxicity in alternate organs (Rutkowski,
Stern and Scherer, 2015). Expandability can be considered through two
mechanisms: hypertrophy and hyperplasia. Hypertrophy is the expansion of
fat mass due to an increase in adipocyte size, and hyperplasia is due to
increased adipocyte number or differentiation (Rutkowski, Stern and Scherer,
2015). The relative turnover of mature adipocytes or induction of adipocyte
differentiation in adults is considered low (Spalding et al., 2008). Therefore,
the effects of environmental exposures, Deltamethrin and BDE-99, and the
beneficial effects of dietary restriction or CR on Nrf2 expression and WAT lipid
metabolism can be summarized considering the changes in expandability of
WAT.
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Hyperplasia within AT can be considered directly related to the ability of preadipocytes to differentiate to adipocytes. Hyperplasia is essential for AT
expandability, but because of low turnover may not be directly to human
exposure models. Therefore, much of the research considers obesity as being
directly related to hypertrophy of adipocytes (La Merrill, Emond, Kim, Antignac,
Le Bizec, Clement, Birnbaum and Barouki, 2013). The two environmental
chemicals presented in this dissertation support the importance of AT
expandability and the potential chemical effects that can result in AT
dysfunction due to hypertrophy. MANUSCRIPT III demonstrated that
regulation of WAT expandability can be altered during development.
Deltamethrin significantly decreased adipogenic, lipogenic, and glucose
uptake gene expression in adult mice exposed perinatally. This did not result
in a phenotypic change, but with a HFD-challenge could demonstrate the
physiological relevance of inhibited AT expandability. MANUSCRIPT II
findings showed that the environmental compound BDE-99 can increase AT
hypertrophy in vitro in both mice and humans. This was demonstrated by no
significant findings in AT differentiation, but a marked increase in lipogenic
gene expression and lipid deposition in BDE-99 treated cells. This manuscript
supports previous findings and studies that identify compounds as obesogens
(La Merrill, Emond, Kim, Antignac, Le Bizec, Clement, Birnbaum and Barouki,
2013). Lastly, MANUSCRIPT I exemplified CR as an effective treatment to
decrease WAT mass and lipid content through mechanisms directly related to
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the antioxidant response in order to achieve homeostasis where energy intake
does not exceed energy expenditure.
Most significantly, all three manuscripts support a novel role for Nrf2 regulation
in WAT expandability and lipid homeostasis. Environmental exposures of
deltamethrin and BDE-99 that predispose or contribute to AT hypertrophy,
respectively, were correlated to decreased Nrf2 gene expression. While, AT
homeostasis achieved by CR was shown to induce Nrf2 gene expression and
key pathways of lipid metabolism were demonstrated to be Nrf2-dependent.
This dissertation supports the role of Nrf2 to achieve AT homeostasis,
maintain lipid homeostasis, and prevent against AT hypertrophy that can result
in obesity and metabolic syndrome.
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